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AUA American Urological Association 
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BRAF B-RAF proto-oncogene, serine/threo-
nine kinase
CBI checkpoint blockade immunotherapy
CIRB National Cancer Institute Central Insti-
tutional Review Board
CIS carcinoma in situ 
CLIA Clinical Laboratory Improvement 
Amendments of 1988
CR complete response 
CTLA-4 cytotoxic T-lymphocyte–associated an-
tigen 4 
CTPM Clinical Trials Planning Meeting
CTSU Cancer Trials Support Unit 
DFS disease-free survival
DNA deoxyribonucleic acid
DSS disease-specifi c survival 
EAU European Association of Urology 
tSWOG Statistical Center, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
uCoordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD, USA
vThe Emmes Corporation, Rockville, MD, USA
wDepartment of Urology, Radboud UMC, Nijmegen, The Netherlands
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Abstract. The NCI Bladder Cancer Task Force convened a Clinical Trials Planning Meeting (CTPM) Workshop focused 
on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (NMIBC). Meeting attendees included a broad and 
multi-disciplinary group of clinical and research stakeholders and included leaders from NCI, FDA, National Clinical 
Trials Network (NCTN), advocacy and the pharmaceutical and biotech industry. The meeting goals and objectives were 
to: 1) create a collaborative environment in which the greater bladder research community can pursue future optimally 
designed novel clinical trials focused on the theme of molecular targeted and immune-based therapies in NMIBC; 2) 
frame the clinical and translational questions that are of highest priority; and 3) develop two clinical trial designs focusing 
on immunotherapy and molecular targeted therapy. Despite successful development and implementation of large Phase II 
and Phase III trials in bladder and upper urinary tract cancers, there are no active and accruing trials in the NMIBC 
space within the NCTN. Disappointingly, there has been only one new FDA approved drug (Valrubicin) in any bladder 
cancer disease state since 1998. Although genomic-based data for bladder cancer are increasingly available, translating 
these discoveries into practice changing treatment is still to come. Recently, major efforts in defi ning the genomic cha-
racteristics of NMIBC have been achieved. Aligned with these data is the growing number of targeted therapy agents 
approved and/or in development in other organ site cancers and the multiple similarities of bladder cancer with molecu-
lar subtypes in these other cancers. Additionally, although bladder cancer is one of the more immunogenic tumors, some 
tumors have the ability to attenuate or eliminate host immune responses. Two trial concepts emerged from the meeting 
including a window of opportunity trial (Phase 0) testing an FGFR3 inhibitor and a second multi-arm multi-stage trial 
testing combinations of BCG or radiotherapy and immunomodulatory agents in patients who recur after induction BCG 
(BCG failure).
Keywords: Non-muscle invasive bladder cancer, trial design, targeted therapy, immunotherapy, radiation therapy
EBRT external beam radiation therapy 
ECOG- ECOG-ACRIN Cancer Research 
 ACRIN  Group (Eastern Cooperative Oncology 
Group and American College of 
Radiology Imaging Network)
EGF epidermal growth factor 
EGFR epidermal growth factor receptor
EMT epithelial-to-mesenchymal transition
ERBB2 Erb-B2 receptor tyrosine kinase 2 gene
ERCC2 excision repair cross-complementation 
group 2
FDA  U.S. Food and Drug Administration
FFPE formalin-fi xed, paraffi n-embedded 
FGFR3 fi broblast growth factor receptor 3
FNIH Foundation for the National Institutes 
of Health
GM-CSF granulocyte macrophage colony-stimu-
lating factor
GU genitourinary
HGF hepatocyte growth factor
HSP90 heat shock protein 90
IBCG International Bladder Cancer Group 
IFN-γ interferon gamma
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IHC immunohistochemistry 
LG low grade
MAP mitogen-activated protein 
MDSC myeloid derived suppressor cells
MHC  major histocompatibility complex
MIBC muscle invasive bladder cancer
MMC mitomycin-C
mRNA messenger ribonucleic acid
NCI National Cancer Institute
NCI- National Cancer Institute’s Coordinating
 CCCT Center for Clinical Trials
NCI- NCI Molecular Analysis for Therapy 
 MATCH Choice 
NCTN  National Clinical Trials Network
NMI non-muscle invasive 
NMIBC non-muscle invasive bladder cancer
NMIUC non-muscle invasive urothelial cancer
NRG1 neuregulin-1
NSCLC non-small cell lung cancer
PCR polymerase chain reaction
PD programmed cell death protein
PD-L1 programmed cell death-ligand1 protein 
PI Principal Investigator 
PIK3CA phosphatidylinositol-4,5-bisphosphate 
3-kinase catalytic subunit alpha gene
RAF rapidly accelerated fi brosarcoma proto-
oncogene
RCC renal cell carcinoma 
RNA ribonucleic acid
RT radiation therapy
STAMPEDE Systemic Therapy in Advancing or 
Metastatic Prostate Cancer: Evaluation 
of Drug Effi cacy: A Multi-Stage Multi-
Arm Randomised Controlled Trial 
SUO Society for Urologic Oncology
SWOG Southwest Oncology Group
SYNPO2 synaptopodin 2 gene
TCC transitional cell carcinoma
TCGA The Cancer Genome Atlas project
TGFα transforming growth factor alpha
TIL tumor infi ltrating cells 
TKI tyrosine kinase inhibitor
TMA tissue microarray
TNF tumor necrosis factor
TUR transurethral resection 
TURBT transurethral resection of bladder tumor
UC urothelial cancer
VEGF vascular endothelial growth factor
WHO/ISUP World Health Organization/Interna-
tional Society of Urological Pathology
SESSION : INTRODUCTION 
AND OVERVIEW
STATE-O F-THE-ART AND CHALLENGES 
OF NON-MUSCLE-INVASIVE BLADDER 
CANCER (NMIBC)
Seth P. Lerner, M.D., FACS
The Bladder Cancer Task Force and the National 
Cancer Institute (NCI) organized a 2-day Clinical 
Trials Planning Meeting (CTPM) Workshop focused 
on Novel Therapeutics for Non-Muscle Invasive 
Bladder Cancer (NMIBC). This meeting brought 
together the multi-disciplinary clinical and research 
community including leaders from NCI, Food and 
Drug Administration (FDA), National Clinical Tri-
als Network (NCTN), and the pharmaceutical and 
biotech industry. Our expressed goals were to de-
velop therapeutic strategies around the theme of 
molecular targeted and immunotherapy based thera-
pies in NMIBC.
The Task Force was constituted in 2010 with the 
mission to evaluate and facilitate development and 
implementation of large Phase II and Phase III trials 
in bladder and upper tract cancers (Table 1). Despite 
this success there are no active and accruing trials 
in the NMIBC space within the NCTN. Furthermore 
there has been only one new FDA approved drug 
(Valrubicin) in any bladder cancer disease state 
since 1998. 
BCG (Tice and TheraCys) was approved for treat-
ment of patients with CIS and high-grade papillary 
NMIBC in 1989 and 1990, respectively. There have 
been well-documented North American and global 
shortages due to disruptions in manufacturing and 
supply that have had a considerable adverse impact 
on our patients. This is an additional driver of in-
novation and drug development that is the subject 
of this important meeting. 
We do however have a good understanding of the 
biology and related natural history of NMIBC. Risk 
stratifi cation schemes and a revised grading system 
simplify assessment of probabilities of recurrence 
and progression and drive treatment decision mak-
ing. Quality metrics for transurethral resection 
(TUR) and re-TUR in the case of high-grade T1 
disease have been established and incorporated into 
guidelines. Urine cytology has a high positive pre-
dictive value for high-grade cancer, especially car-
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cinoma in situ, and there are several FDA-approved 
voided urine biomarkers and novel detection system 
(e.g. fl uorescence cystoscopy) that can be used as 
an adjunct to white light cystoscopy for detection 
of bladder cancer. 
There is a robust track record of clinical trials in 
NMIBC that provide high level evidence supporting 
the current standard of care. Bacille-Calmette Guerin 
(BCG) is approved for treatment of high-grade pap-
illary disease (Ta, T1) and carcinoma in situ (CIS). 
Table 1
Bladder Task Force activity since 2010
Current Active Trials
• RTOG-0926 – Chemo XRT for T1HG 
•  S1314 – COXEN neoadjuvant chemotherapy prior to 
radical cystectomy
•  NRG-GU001 – Adjuvant XRT post RC for patients at 
high risk for local pelvic recurrence
•  ECOG EA8141 – Phase II trial of neoadjuvant 
chemotherapy for upper tract urothelial carcinoma 
• NRG-GU-TS001 – MRE11 retrospective validation 
Concepts Reviewed and in Development
• SWOG 1602 (PRIME)
• MATCH-UP (Alliance) – NCI declined to move forward
• Adjuvant Pembrolizumab (Alliance) 
• Chemo/XRT MIBC - MRE-11 prospective validation
• SWOG 1605 - Anti-PD-L1 for BCG unresponsive disease
A 6–week induction course is superior to TURBT 
alone (Level 1A) and is associated with an initial 
complete response in 50-70% of patients. A second 
induction course may achieve a complete response 
in an additional 10-22% of patients  (Level 3) and 
patients who relapse > 1 year following an initial 
complete response (CR) can be effectively treated 
with re-induction with BCG. However, patients with 
CIS who recur after 2 course of BCG should not be 
treated with a third course, as durable CR rates are 
low (Level 2B). Maintenance therapy with 3 week-
ly instillations followin g induction therapy at months 
3,6 and every 6 months to 3 years is associated with 
improved RFS and PFS compared to induction 
therapy alone and is the current standard of care for 
high-risk disease (SWOG, 8507; Level 1B). The 
recent EORTC 30962 trial provided additional data 
to support the use of 3 years of maintenance with 
high-risk disease. BCG is also superior to intraves-
ical chemotherapy with mitomycin (Level 1A) and 
epirubicin (Level 1B), but only when maintenance 
therapy is used. 
The FDA and the urologic oncology community 
have provided guidance regarding clarifi cation of 
disease states post BCG treatment for inclusion in 
registration trials in NMIBC [1–4]. BCG failure is 
defi ned as patients with recurrent or persistent dis-
Table 2
Current clinical trial landscape
Trial/Sponsor Drug Target/Design Phase Status
S0337 Gemcitabine Peri-op single dose III Completed
NCT00974818 MMC vs. Gem Closed early?
NCT00461591
NCT00598806
Apaziquone Peri-op single dose III Closed
RTOG-0926 Chemo/XRT T1 II Open
NCT01732107 Dovitinib (FGFR3) BCG refractory II Closed
Cold Genysis CG 0070 Rep competent ADV GMCSF III Open?
NCT02009332 Rapamycin (mTOR) BCG refractory I/II Open
NCT01259063 Everolimus/Gem BCG refractory/CIS I/II Open
NCT02197897 Tamoxifen ER – TaLG marker lesion II Open
NCT02010203
Heat Biologics
HS 410 (vaccine) BCG + HS 410 
(BCG naïve)
I/II Open
Viventia Vicinium High risk I/II Ph II planned
FKD AD-IFN BCG refractory II Completed
Ph III planned
BioCancell BC 819 (H19/DTA) BCG failure/refractory II Completed 
Ph III planned
NCT02015104 PANVAC+BCG vs. BCG BCG failure II Open
Telesta Therapeutics MCNA Failure/Unresponsive III Completed
Altor Bioscience ALT-803 (IL15) BCG naïve I/II Completed
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ease following the fi rst induction therapy. BCG un-
responsive is defi ned as patients who recur after a 
minimum treatment of induction plus one course of 
maintenance therapy or patients who never achieve 
a CR within 6 months of the last BCG treatment. 
Patients who recur with T1HG after induction only 
are also considered unresponsive. The standard of 
care for these patients is radical cystectomy and so 
there is a large unmet need for drug development in 
this space. Valrubicin is the only approved drug for 
patients with CIS who are BCG-refractory and re-
fuse or are determined to be too high a medical risk 
for cystectomy. The future is bright however, as 
there is intense interest from a broad array of phar-
maceutical companies and there are novel drug de-
livery systems being deployed as well (Tables 2, 3). 
In the past 3 years there has been a convergence 
of output from diverse sources delineating the ge-
nomic landscape of urothelial bladder cancer, cul-
minating with the recent publication of the “marker” 
paper from The Cancer Genome Atlas project in 
muscle invasive disease [5]. Maggie Knowles and 
others have sought to defi ne the genomic character-
istics of NMIBC along pathways that distinguish 
low grade from high-grade disease [6]. The Lund 
group has provided additional clarifi cation describ-
ing an immunohistochemical classifi er for high-
grade T1 disease stratifying into urobasal and GU 
squamous cell like subtypes [7]. Aligned with these 
data is the growing number of targeted therapy 
agents approved and/or in development in other or-
gan site cancers and the multiple similarities of blad-
der cancer with molecular subtypes in these other 
cancers. Additionally, although bladder cancer is 
one of the more immunogenic tumors seen in man, 
some tumors have the ability to attenuate or elimi-
nate host immune responses. 
Supplemental material is provided to share the 
Goals and Meeting Agenda.
T able 3
Novel drug delivery systems
• Adenoviral mediated
• PEI/DNA plasmid
• Liposomal complex
• Nanoparticles
• Implantable osmotoic pump
• Conjugated antibody/payload
• Bacterial minicells
• Heat
• Iontophoresis
• Muco-adhesive molecules
LESSON S FROM ADVANCED DISEASE 
TRIALS APPLICABLE TO NMIBC
Dean F. Bajorin, M.D. 
The Clinical Trial Planning Meeting for non-
muscle invasive bladder cancer is a unique oppor-
tunity provided by the National Cancer Institute to 
bring together leaders in the fi eld including coop-
erative group investigators, academia, industry, pa-
tient advocacy, and offi cials from FDA and NCI to 
spur the development of state of the art trials in 
non-muscle invasive bladder cancer. We are familiar 
with four major disease states seen in urothelial can-
cer ranging from non-muscle invasive bladder can-
cer to muscle invasive bladder cancer to metastatic 
disease treated with fi rst-line therapy to the meta-
static disease treated with salvage or second line 
therapy. We know from past experience in many 
malignancies that novel drugs active in the chemo-
therapy refractory metastatic disease setting can be 
escalated to earlier stage disease. Such is the case 
for bladder cancer in that novel treatment modalities 
identifi ed as active in the chemotherapy refractory 
disease state have good rationale for clinical studies 
seeking to advance treatment in patients with non-
muscle invasive bladder cancer. 
We are fortunate in that bladder cancer is in the 
midst of a perfect storm, i.e., the emergence of 
comprehensive molecular characterization of uro-
thelial carcinoma coupled with major advances in 
both targeted therapy and immunotherapy. The 
Cancer Genome Atlas Project (TCGA) for muscle 
invasive bladder cancer was published this past year 
and was highly informative with regard to both tu-
mor biology and potential clinical interventions [6]. 
That study reported a large number of potentially 
actionable mutations in multiple pathways previ-
ously exploited in other diseases. For example, 93% 
of patients’ tumors demonstrated alterations in the 
p53/RB1 pathway. These included alterations in 
CDKN2A, ATM, RB1, and E2F3. Similarly, 72% 
of tumors in this study had alterations in the RTK/
RAS/PI(3)K pathway. This latter pathway is par-
ticularly opportune based on reported responses 
seen with tyrosine kinase inhibitors to TSC 1 and 
FGFR 3, respectively. In a phase 2 study of evero-
limus in previously treated patients, this mT0RC1 
inhibitor resulted in a complete response in a patient 
with disease refractory to gemcitabine and cispla-
tin. Whole genome sequencing performed in this 
patient demonstrated both TSC1 and NF2 mutations 
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identifi ed as cooperative and resulting in exquisite 
sensitivity to this agent. Additionally, other studies 
have reported responses to inhibitors of FGFR3 and 
PIK3CA inhibitors. We know now that many tu-
mors harbor multiple alterations within the same 
pathway and it may be unknown whether an al-
teration is a driver or passenger mutation. Thus, 
sequential biopsies will be critical to dissect mech-
anisms of sensitivity and resistance in any proposed 
trial. 
The other emerging treatment opportunity is the 
use of immunotherapy agents active in the pro-
grammed cell death (PD) pathway responsible for 
suppressing antitumor immunity. At the time of this 
symposium, the fi rst report of a drug active in ad-
vanced bladder cancer has been published. This 
initial study explored MPDL3280A in the treatment 
of patients whose cancer had progressed despite 
chemotherapy. Signifi cant responses were observed 
– initial results demonstrated that responses were 
greater in patients whose tumors expressed PD-L1 
staining in tumor infi ltrating cells. The initial study 
reported a response rate of 43% in tumors with high 
expression of PD-L1 and 11% in tumors with little 
or no expression of PD-L1. Most remarkable in the 
study was the duration of responses, some extending 
well beyond one year. Prolonged response to any 
chemotherapy agent in this disease state is distinct-
ly unusual and rarely reported in the literature mak-
ing this a very promising intervention to exploit 
across all disease states. 
Investigators studying urothelial cancer can ben-
efi t from other studies of immunotherapy in different 
malignancies, specifi cally melanoma and non-small 
cell lung cancer. These studies demonstrate that 
other molecular markers of response besides PD–L1 
may exist. For example, studies in both melanoma 
and non-small cell lung cancer demonstrate that a 
high mutation rate in these tumors may be prognos-
tic. Interestingly, urothelial cancer has a very high 
somatic mutation rate similar that seen in melanoma 
and non-small cell lung cancer. In the case of non-
small cell lung cancer, a distinct molecular smoking 
signature associated with durable benefi t has been 
reported. Conversely, neoantigens identifi ed in mel-
anoma appear to have similarities to antigens ex-
pressed in infectious diseases. Both of these studies 
are early reports of companion diagnostics, ap-
proaches that may help us distinguish prospectively 
those patients who may benefi t from immunothera-
py in urothelial cancer. 
Urothelial cancer is poised for innovative and 
potentially effective therapy in the advanced disease 
setting which may be clinically applied to the non-
muscle invasive bladder cancer disease state. Ad-
ditionally, bladder cancers are accessible for biopsy 
that will allow us to interrogate these tumors to 
make further advances both in urothelial cancer as 
well as other malignancies. Ou r challenge for this 
symposium is to create the platform for studying 
these novel drugs in non-muscle invasive bladder 
cancer. Both immunotherapy drugs and novel tyro-
sine kinase inhibitors are given systemically rather 
than by an intravesical route. Therefore, expertise is 
needed in both administration and management of 
unique toxicities and clinical trials will require en-
hanced collaborations between urologists and med-
ical oncologists. These fi rst-generation trials will 
need to extend our biological understanding of these 
new drugs in urothelial cancer and thus will require 
enhanced collaborations between physicians and 
translational scientists to establish sustainable re-
search platforms for subsequent trials. 
Our charge to the participants of the clinical trial 
planning meeting is to spur the development of two 
separate trial concepts to be exploited in the coop-
erative group mechanisms. The proposed trials will 
seek to test two hypotheses: 1) Molecularly targeted 
therapy has clinical benefi t in non-muscle invasive 
bladder cancer; and, 2) Novel immunotherapy has 
clinical benefi t in non-muscle invasive bladder can-
cer. Throughout the planning meeting, clinicians, 
scientists, government agencies, pharmaceutical ex-
perts, and patient advocates convened to plan how 
best to test each hypothesis within the cooperative 
group clinical trial mechanism.
INTEGR ATING RADIATION FOR NMIBC: 
CURRENT STATUS AND FUTURE 
OPPORTUNITIES
Jason A. Efstathiou, M.D., D.Phil.
Management of high-risk NMIBC, especially 
when recurrent after BCG, is complicated by poor 
long-term response rates to alternative intravesical 
biologic/chemotherapeutic agents and regimens. 
 Although radical cystectomy remains standard, 
 national practice patterns suggest that many patients 
are not getting cystectomy when indicated, likely 
due to age, comorbidities and/or desire to avoid such 
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surgery [8]. Further compounding this dilemma is 
that a substantial proportion (~45%) of T1 tumors 
are actually upstaged at time of surgery [9] suggest-
ing that more defi nitive local therapy may indeed 
be indicated. 
Combined modality therapy using chemoradia-
tion has long been utilized as a curative therapy for 
MIBC [10]. Although radiation-based therapy is not 
standard in NMIBC, it may offer an alternative for 
selected patients who are otherwise unfi t or unwill-
ing to undergo cystectomy. In T1 bladder cancer, 
early studies using radiation therapy (RT) alone 
demonstrated response rates of 48-69% for unifocal 
tumors [11, 12]. A subsequent randomized trial of 
RT alone versus conservative treatment for high-
grade T1 tumors showed no difference in terms of 
recurrence (local failure rates ~70% in both arms) 
or survival; however, this study was limited due to 
long accrual and lack of control over TUR extent 
and time to adjuvant therapy [13].
The experience of using combined chemoradia-
tion following an attempt at maximal TUR as an 
alternative primary treatment for high-risk NMIBC 
is more encouraging. The University of Erlangen 
[14] reported on their institutional experience of 141 
patients. They demonstrated a complete response 
rate of 88%; progression rates of 19% and 30% 
(13%/29% for high-grade T1 tumors) at 5- and 
10-years, respectively; and disease-specifi c survival 
(DSS) rates of 82% and 73% (89%/79% for com-
plete responders and 80%/71% for high-grade T1 
tumors) at 5- and 10-years. Over 80% of survivors 
preserved their native bladder, and ~70% were ‘de-
lighted’ or ‘pleased’ with their urinary function. Of 
note, this was an experience of alternative primary 
treatment (i.e. not limited to salvage for BCG refrac-
tory disease). The Massachusetts General Hospital 
reported on an experience of 17 patients undergoing 
TURBT and chemoradiation following T2 recur-
rence after failing BCG for non-invasive disease 
[15]. With 7-years follow-up, only 1 patient required 
cystectomy, 10 (59%) were free of any bladder re-
currence, and DSS was 70%. To further inform the 
role of chemoradiation in NMIBC, there is cur-
rently an ongoing prospective cooperative group 
protocol RTOG-0926 evaluating 61.2 Gy plus con-
current cisplatin or 5FU/MMC after maximal 
TURBT for patients with high-risk T1 bladder can-
cer who recur following BCG [16]. 
Although at this time there is limited data in blad-
der cancer, RT is known to have multiple immune-
mediated effects making the combination of RT and 
immunotherapy a promising avenue for enhanced 
response that warrants further investigation. RT 
helps liberate antigen and mature dendritic cells for 
effective T-cell priming, and the addition of immu-
notherapeutic agents (such as checkpoint inhibitors 
- anti-PDL1, anti-PD-1, anti-CTLA-4) could en-
hance the immunostimulatory effects of RT and thus 
improve tumor control [17]. One study demonstrat-
ed that the addition of GM-CSF to local RT di-
rected at metastatic sites of different solid tumors 
produced objective abscopal responses in 27-28% 
of patients [18]. Current data from pre-clinical mod-
els support concurrent administration of RT plus 
immunotherapy and hypofractionated regimens, 
though abscopal effects have been observed even 
with single large RT doses such as 8Gy x1 [17, 18].
In summary, radiation combined with chemother-
apy or immune checkpoint inhibitors holds promise 
for improved tumor control and enhanced immuno-
logic response, and may help fi ll the need for alter-
native potentially curative therapies in selected pa-
tients with recurrent high-risk NMIBC. Biomarkers 
of radiation response may further identify subgroups 
of patients best served by such  approaches. 
OPPORT UNITIES FOR EMBEDDING 
BIOMARKERS IN PROSPECTIVE TRIALS 
OF NON-MUSCLE INVASIVE BLADDER 
CANCER (NMIBC)
Lisa McShane, Ph.D.
There are numerous opportunities for develop-
ment of biomarkers or biomarker signatures to 
 optimize care for patients with NMIBC (Table 4). 
Important roles that biomarkers could play include 
prognostic indicators, predictive (treatment selec-
tion) indicators, and monitoring indicators for use 
during or after initial treatment [19]. These biomark-
ers could potentially be measured in tumor tissue, 
normal bladder epithelium, urine, or blood. Biomark-
er development should focus not merely on identifi -
cation of biomarkers with statistically signifi cant 
associations with clinical outcomes but should pro-
vide information that can be acted upon clinically 
and lead to better outcome for patients [20].
Clinically useful biomarkers provide actionable 
information that is not already available from stan-
dard clinico-pathologic indicators, or they provide 
information comparable to standard indicators less 
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invasively or with lower cost or greater convenien-
ce. The anatomic accessibility of the bladder 
 epithelium allows for biomarkers to be readily mea-
sured in tumor tissue or in morphologically normal 
appearing bladder epithelium during biopsy. Bio-
markers are needed for low-grade Ta disease to 
identify which patients have the highest likelihood 
of disease recurrence and might benefi t from recei-
ving intravesical therapy following tumor resection. 
For high grade stage Ta and stage CIS bladder can-
cers likely to be treated with intravesical therapy, 
predictive biomarkers are needed to select optimal 
therapeutic agents and frequency and duration of 
therapy to increase chances of disease eradication, 
lower chances of adverse effects of treatment, and 
decrease the need for subsequent cystectomy. An 
important therapeutic decision for patients with sta-
ge T1 disease is whether to have full or partial 
cystectomy or to fi rst consider intravesical immu-
notherapy or chemotherapy. The possibility to de-
tect tumor cells or secreted biomarkers in urine or 
blood also presents opportunities to identify bio-
markers for non-invasive early monitoring of ro-
bustness of response to therapy or for early detec-
tion of disease recurrence or progression. 
Collectively, these opportunities make non-muscle 
invasive bladder cancer fertile ground for biomarker 
development and validation. 
SESSION I: KEY GENETIC TARGETS 
AND RELEVANT PATHWAYS FOR 
INTERVENTION IN BLADDER 
CANCER
Session Co-Chairs: David Kwiatkowski, MD, PhD, 
Colin Dinney, MD, Jonathan Rosenberg, MD
OVERVIEW O F MOLECULAR 
ALTERATIONS IN BLADDER CANCER - 
MIBC VS. NMIBC
David Kwiatkowski, MD, PhD
Several recent comprehensive genome-wide anal-
yses have identifi ed multiple genes and pathways 
involved in bladder cancer development [5, 21–24]. 
These studies have revealed that bladder cancer has 
a high mutation rate largely due to APOBEC-medi-
ated mutagenesis. Over 30 genes are commonly 
mutated in invasive bladder cancer including those 
in the cell cycle, chromatin regulatory, PI3K-mTOR, 
Ras, receptor tyrosine kinase, and transcription reg-
ulatory pathways. Focal genomic amplifi cations and 
deletions are also common in bladder cancer and 
target these same pathways. Previous studies have 
shown that FGFR3 mutations are more common in 
Table 4
Priority opportunities for biomarker-based tests to have clinical impact in non-muscle invasive bladder cancer
Disease state Specimen type Biomarker clinical use Example clinical study
Stage 0a (Ta), 
low risk
Tumor or normal 
bladder epithelium
Prognostic biomarkers to 
identify patients at high risk 
of recurrence or progression
Establish whether patients indicated by biomarkers to 
be high risk benefi t from intravesical therapy following 
tumor resection
Stage 0a (Ta), 
high risk
Tumor or normal 
bladder epithelium
Predictive biomarkers to 
select optimal therapy
Establish whether biomarkers can optimally select 
among treatment options including intravesical 
immunotherapy or chemotherapy
Stage 0is (CIS) Tumor or normal 
bladder epithelium
Predictive biomarkers to 
select optimal therapy
Establish whether biomarkers can optimally select 
among different intravesical therapy options, including 
various immunotherapies or chemotherapies as well as 
frequency and duration of therapy 
Blood or urine Intra-treatment monitoring 
to detect response or 
non-response
Establish whether switching therapy based on 
biomarkers measured during therapy that indicate lack 
of response leads to a lower rate of non-response or 
progression than not acting on the biomarkers 
Stage I (T1) Tumor or normal 
bladder epithelium
Predictive biomarkers to 
select optimal therapy
Establish whether biomarkers can optimally select 
among treatment options including cystectomy (full or 
partial), or various intravesical immunotherapies or 
chemotherapies 
All stages Blood or urine Post-treatment surveillance Establish whether biomarkers measurable in blood or 
urine can replace or reduce frequency of surveillance 
cystoscopies without increasing rate of poor outcomes 
associated with recurrent or progressive disease 
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NMIBC, while TP53 mutations are more common 
in muscle-invasive (MIBC) bladder cancer. Compi-
lation of data from four studies employing whole 
exome sequencing [5, 21, 22, 24] including a total 
of 350 MIBC cases and 54 NMIBC cases indicates 
that both KDM6A and FGFR3 mutations are sig-
nifi cantly more common in NMIBC than MIBC 
(42% vs. 23%, and 22% vs. 11%, respectively), 
while TP53 and MLL2 are signifi cantly more fre-
quent in MIBC than NMIBC (47% vs. 22%, and 
22% vs. 4%, respectively) (Fig. 1). Mutations in 
several other genes also appear to be more common 
in MIBC but did not reach statistical signifi cance: 
ERBB3, CDKN1A, CDKN2A, NFE2L2, TXNIP. 
Other studies have identifi ed STAG2 mutations as 
occurring more often in NMIBC vs. MIBC.
These fi ndings confi rm the common model that 
NMIBC and MIBC develop through distinct mo-
lecular pathways, and suggest that only a fraction 
of MIBC progresses from precursor NMIBC  tumors.
FGFR3 AND F USION PARTNERS AS 
POTENTIAL TARGETS – EXAMPLES OF 
HIGHLY TARGETABLE MUTATIONS
Margaret Knowles, BSC, PhD 
FGFR3 has been implicated in NMIBC for more 
than a decade. Sixty to 70% of stage Ta tumors and 
approximately 40% of stage T1 tumors have activat-
ing point mutations (most commonly S249C) that 
induce ligand-independent signaling. In addition, 
some tumors without point mutation (10-15%) show 
up-regulated FGFR3 protein expression [25] (Fig. 2) 
[26]. Oncogenic FGFR3 fusion proteins have been 
identifi ed in approximately 2–4% of bladder cancers 
overall. Their grade/stage distribution remains un-
clear, but it is notable that the fusions we have found 
in bladder cancer cell lines (RT4, RT112, LUCC2, 
SW780) are in lines derived from grade 1 or 2 tu-
mors or tumors described as “papillary” [27]. Taken 
together, FGFR3 is implicated in >80% of stage Ta 
and >50% of stage T1 tumors.
The reported consequences of FGFR3 activation 
in normal urothelial cells are activation of the RAS-
MAPK pathway and PLCγ but not the phosphati-
dylinositol 3-kinase pathway. FGFR3 has been ex-
amined as a potential therapeutic target by shRNA 
knockdown and treatment with small molecule in-
hibitors and antibodies using in vitro assays and in 
vivo xenograft assays. Although normal urothelial 
cells express low levels of FGFR3, they are not 
sensitive to the small molecule inhibitors tested 
(PD173074, AZD4547, TKI-258). Tumor cell lines 
with point mutation and detectable FGFR3 protein 
expression show variable responses (e.g. IC50 for 
PD173074 from 10-1000nM). Three cell lines with 
FGFR3 fusions (RT4, RT112 and SW7800) show 
Fig. 1. Comparison of mutation frequencies in non-muscle invasive (NMI) vs. muscle invasive bladder 
cancer (MIBC). Mutation frequencies are shown for genes for which there were some evidence for a dif-
ference in mutation frequency between NMI and MIBC. P is conventional p values by Fisher exact text; 
q is values after correction by FDR for multiple comparisons. 
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high sensitivity (IC50 5-50nM). In these sensitive 
cell lines, cell cycle arrest rather than apoptosis is 
induced. Similarly, in xenograft assays, FGFR1/3 
selective small molecules induce a cytostatic rather 
than a cytotoxic response, with tumor escape fol-
lowing cessation of treatment [28]. 
Potential resistance mechanisms have been ex-
amined in several studies. RT112 (FGFR3 fusion-
containing) can be rescued from the inhibitory ef-
fects of PD173074 by NRG1 and EGF, and from 
BGJ398 by HGF, NRG1, TGFα and EGF. EGFR 
knockdown was found by RNAi screening to in-
crease sensitivity to PD173074 in FGFR3-depen-
dent cell lines. Conversely, FGFR3 provided escape 
from EGFR inhibition in EGFR-dependent cell 
lines, and combined inhibition of EGFR and FGFR3 
had synergistic effect [29]. This cross talk between 
EGFR and FGFR3 signaling has also been demon-
strated by the high sensitivity of RT112 to HSP90 
inhibition, which caused down regulation of both 
of these client proteins. Importantly, HSP90 inhibi-
tion induced apoptosis rather than cell cycle arrest 
[30]. 
TARGETABLE ALTER ATIONS IN NMIBC
William Kim, M.D.
Recent publications have comprehensively char-
acterized the landscape of genomic alterations in 
high-grade, muscle-invasive bladder cancer (MIBC) 
and found that these tumors have a high prevalence 
of alterations that are potentially treatable by tar-
geted therapy. Past reports have also examined 
copy number alterations and mutations in non-
muscle invasive bladder cancer. We collated the 
three largest datasets that contained high-grade, 
NMIBC to make the following observations [31–
33]. 1) Very few CIS samples have been profi led. 
2) Comparison of the mutational frequency be-
tween NMIBC and MIBC showed that a number 
of genes (most notably FGFR3) are more frequent-
ly mutated in high-grade, NMIBC (Fig. 3). 3) The 
majority of NMIBC, like MIBC, harbor alterations 
in pathways that are potentially treatable with tar-
geted therapy and a small fraction of tumors may 
be amenable to combination therapy. While these 
Fig. 2. R elationship of FGFR3 mutation and expression in non-muscle invasive bladder cancer. Expression of 
FGFR3 protein (low or high) detected by immunohistochemistry in relation to presence or absence of FGFR3 
point mutations (mutant vs. WT) in stage Ta and T1 bladder tumors (Data from Tomlinson, 2007 [26].)
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results suggest the potential for the use of targeted 
therapy in HG, NMIBC, unresolved issues remain 
including the unknown degree of intratumoral het-
erogeneity and how to best prioritize competing 
mutations. Finally, recent research suggests that 
mutations in the DNA damage repair pathway may 
predict for response to cisplatin based chemother-
apy in MIBC. Intriguingly, mutations in these genes 
appear to be present in NMIBC as well suggesting 
a potential utility for intravesical cytotoxic chemo-
therapy. 
DEFINING THE ACTI ONABLE GENOME
David Solit, M.D.
Bladder cancer is a genomically heterogeneous 
disease. Recent studies have identifi ed frequent mu-
tations in several targetable kinases including 
FGFR3, ERRB2, PIK3CA and others [34]. As each 
of these genes is mutated in only a minority of pa-
tients, novel clinical trial designs are needed to ef-
fi ciently test inhibitors of these driver oncogenes in 
patients with advanced bladder cancer. 
Basket studies are trials in which eligibility is based 
not upon site of tumor origin but rather the presence 
or absence of a particular genetic mutation. For ex-
ample, in the recently reported vemurafenib basket 
study, patients with multiple non-melanoma cancers 
whose tumor harbored a codon 600 BRAF mutation 
were eligible [35]. This study confi rmed that BRAF 
was a targetable oncogene in some, but not all, non-
melanoma cancers. The basket design was shown to 
be particularly effi cient for testing this agent in rare 
tumor types. Given the genomic heterogeneity of 
bladder cancers, a collection of basket studies (a tent 
protocol) could be the optimal way to test genotype-
phenotype correlations. In such a design, patients 
could be screened using a central reference labora-
tory or locally in a CLIA-regulated laboratory. Pa-
tients with specifi c mutations would then be eligible 
for genotype matched basket studies that are testing 
novel agents or combinations in particular mutant 
populations. One limitation of this design is that a 
compelling clinical strategy may not be available for 
all mutational subtypes. For example, in patients with 
bladder cancer whose tumors are RB1 mutant, a 
promising targeted approach has yet to be identifi ed. 
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Fig. 3. Pathwa y alterations in HG, NMIBC and potential drugs targeting specifi c alterations.
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INTRINSIC BASAL A ND LUMINAL 
SUBTYPES OF BLADDER CANCER: 
IMPLICATIONS FOR IMMUNOTHERAPY
David McConkey, Ph.D.
Recent high profi le clinical trial results indicate 
that immunotherapy with immune checkpoint in-
hibitors is clinically active in advanced, cisplatin-
refractory muscle-invasive bladder cancers (MIBCs)
[36]. Immunotherapy, in the form of intravesical 
BCG, is also highly active in high-grade NMIBCs 
and remains the frontline therapy for them. There-
fore, there is a surge of new interest in determining 
whether immune checkpoint blockade could also be 
used to improve the clinical outcomes of patients 
with NMIBCs. Translational studies, mostly per-
formed in other solid malignancies (i.e., melanoma, 
NSCLC), are beginning to identify the biological 
determinants that dictate response to these agents. 
Although there is not a strict correlation between 
checkpoint biomarker expression and response, tu-
mors that are enriched with immune checkpoint 
biomarkers (CTLA4, PD1, PDL1) and/or display a 
strong T cell infi ltrate at baseline appear to be more 
likely to respond [37, 38]. The biological determi-
nants of immune checkpoint biomarker expression 
and T cell infi ltration are still under investigation 
but include overall mutational burden [39], epithe-
lial-to-mesenchymal transition (EMT) [40], and 
tumor-specifi c signal transduction pathways (i.e., 
active β-catenin) [41].
Several groups recently demonstrated that MIBCs 
can be assigned to intrinsic basal and luminal sub-
types that are similar to the ones observed in breast 
cancer [5, 42, 43]. The subtypes respond differently 
to conventional chemotherapy [42] and are enriched 
with mutations and other biomarkers that suggest 
that they will also respond differently to targeted 
therapies [44]. In particular, there is a fraction of 
“mesenchymal” (“claudin-low”) basal MIBCs that 
is highly enriched with T and B lymphocyte gene 
expression signatures, including immune checkpoint 
biomarkers including PD-L1 [44]. Conversely, a 
large fraction of luminal MIBCs, corresponding to 
TCGA’s “papillary” subtype (cluster I) that is also 
characterized by enrichment with FGFR3 mutations 
and fusions, expresses particularly low levels of 
these same biomarkers [44], and results from a com-
pleted Phase 2 study of atezolizumab in patients 
with cisplatin-refractory advanced disease con-
fi rmed that these papillary luminal tumors were 
 resistant to PD-L1 blockade [124]. Using whole ge-
nome mRNA expression profi ling, we have found 
that essentially all NMIBCs express similarly low 
levels of lymphocyte and immune checkpoint bio-
markers at baseline, although preliminary compari-
sons of matched tumors before and after BCG im-
munotherapy (n = 5) demonstrated consistent 
increases in CTLA4 expression post-therapy. Fur-
ther investigation is required to defi ne the biological 
determinants of lymphocyte infi ltration, immune 
checkpoint biomarker expression, and sensitivity to 
immune checkpoint blockade across the spectrum 
of bladder cancer disease states. It is anticipated that 
this information will be crucial to informing clinical 
trial design and in interpreting their outcomes.
PATHOLOGICAL ASPEC TS AND TISSUE 
ACQUISITION FOR NEXT GENERATION 
TRIALS IN NMIBC
Hikmat Al-Ahmadie, M.D.
Tissue analysis provides vital information in the 
workup of patient with bladder cancer. One impor-
tant aspect of histopathological tissue evaluation is 
to provide accurate diagnosis, which includes estab-
lishing the presence of tumor (or its absence), as-
signing a grade/classifi cation and providing the 
pathologic stage by assessing the depth of tumor 
invasion when present. These aspects of the patho-
logic evaluation are generally achieved by applying 
criteria proposed by the World Health Organization/
International Society of Urological Pathology 
(WHO/ISUP) that are widely used [45]. In order to 
satisfactorily achieve these goals, adequate tissue 
sampling is required which includes that presence 
of adequate amount of tumor to assign grade and 
properly classify the tumor but also adequately deep 
tissue to properly provide tumor stage. The latter 
point requires the presence of portions of the mus-
cularis propria (detrusor muscle) in the sample, par-
ticularly in invasive tumors, in order to be able to 
rule out its involvement by cancer. 
Other important aspects of the pathologic evalu-
ation of bladder tissue include the application of 
immunohistochemical staining for potential clini-
cally relevant biomarkers or the application of next 
generation sequencing assays on tumor tissue. These 
techniques are becoming increasingly available and 
some have been approved for use in certifi ed  clinical 
settings [46]. This was made possible particularly as 
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the tissue requirement for such analyses are becom-
ing increasingly fl exible, requiring smaller quantities 
of nucleic acid and being suitable for the more abun-
dant formalin fi xed paraffi n embedded tissue. These 
technologies are very powerful and sophisticated and 
can provide vital information about the tumors ge-
netic makeup that can be potentially used for diag-
nostic, prognostic and therapeutic purposes. 
Needless to say that the samples should be of 
good enough quality to enable the pathologist to 
provide this necessary information whether it is for 
diagnosis purposes or for use in any correlative stud-
ies that require tissue evaluation. This includes hav-
ing adequate amount of tumor tissue and also tissue 
that is devoid of signifi cant thermal or autolytic/
ischemic artifacts.
INTEGRATIVE CLINIC AL SEQUENCING 
AND ANALYSIS APPROACHES FOR NMIBC
Eliezer Van Allen, M.D.
Systematic approaches to defi ne the genomic 
landscape of clinically relevant NMIBC genomics 
may differentiate risk of recurrence and identify new 
treatment strategies for this disease. Furthermore, 
given tumor heterogeneity, approaches that utilize 
genome-wide data generation may yield insights 
into NMIBC genomics. 
As proof of principle towards these approaches in 
bladder cancer, we performed whole exome sequenc-
ing on 50 patients with muscle invasive bladder can-
cer (MIBC), half of whom had complete responses 
to neoadjuvant cisplatin-based chemotherapy, the 
other half with persistent muscle invasive disease. 
Through mutation identifi cation and case/control ge-
nomics algorithm development, we discovered and 
experimentally validated that somatic ERCC2 muta-
tions correlated with cisplatin response in MIBC 
[24]. With this approach as a model, we therefore 
propose similar studies in key clinical nodes along 
the clinical pathway for NMIBC [6]. These include 
deep molecular characterization of NMIBC patients 
who do or do not progress through whole exome (and 
potentially transcriptome) sequencing followed by 
case/control genomic analyses. 
Similarly, detailed examination of longitudinally 
acquired NMIBC samples for study of tumor 
 evolution may identify genomic events that trigger 
progression of disease (Fig. 4). We have developed 
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Fig. 4. Schematic f or longitudinal tumor sampling of NMIBC to MIBC progression. This approach may inform genomic 
features of high risk disease and identify new therapeutic targets.
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and applied genomics approaches for studying such 
patients longitudinally in other tumor types, such as 
in BRAF-mutant melanoma and acquired RAF in-
hibitor resistance [47], thereby discovering new ge-
nomic mechanisms of acquired resistance that may 
inform subsequent treatment avenues. A similar stra-
tegy for NMIBC patients towards identifying such 
features in patient-matched samples may enable di-
scovery of molecular switches for NMIBC progres-
sion. Ultimately, this approach may identify high-
risk genomic features and, potentially, new 
therapeutic avenues for this disease.
IDENTIFYING TARGETS TH ROUGH 
GENOME SCALE EPIGENETIC ANALYSIS
Luigi Marchionni, M.D., Ph.D.
Epigenetics is the study of heritable gene function 
changes that cannot be explained by changes in 
DNA sequence. DNA methylation, histone modifi -
cations, chromatin remodeling, and RNA-based 
gene regulation are the most studied epigenetic 
mechanisms. Altered DNA methylation represents 
the most common epigenetic alteration in bladder 
cancer and CpG island hypermethylation of tumor-
suppressor gene promoters is associated with tran-
scriptional inactivation and may occur early in car-
cinogenesis, making it clinically valuable for early 
diagnosis and risk stratifi cation. DNA methylation 
can be studied using either a candidate gene or a 
genome-wide approach, using a number of tech-
niques available to enrich for DNA methylation 
prior to sequencing, microarray, or PCR analysis.
The vast majority of studies of DNA methylation 
in non-muscle invasive bladder cancer (NMIBC) 
have used a gene candidate approach [48, 49]. These 
studies have, therefore, mostly focused on known 
tumor suppressor genes (e.g., CDKN2A (p16-
INK4A and p14-ARF APC, CDH1, BRCA1, WT1, 
TP53), or on candidate suppressor genes (e.g., 
TMP3, RASSF1A, CDH13, Wnt-signaling antago-
nists, DAPK1, Laminins, GSPT1, RUNX3, SPINT2), 
which have shown associations with various clinical 
phenotypes in muscle-invasive bladder cancer or in 
other tumor types (Table 5). Only a few recent stud-
ies have used a genome-wide approach reporting 
multi-gene signatures (as described in a comprehen-
sive review [48, 49]).
Most importantly DNA hypermethylation has 
been shown to carry prognostic information in 
NMIBC, with a variety of selected genes associated 
with disease recurrence, progression, or both (Table 
5). Furthermore, one gene – synaptopodin 2 (SYN-
PO2) – has also been associated with resistance to 
BCG treatment in different cohorts of patients with 
T1G3 bladder cancer. Distinctive methylation pat-
terns have been shown to differentiate between 
Table 5
DNA methylat ion markers in bladder cancer associated with progression or recurrence in NMIBC
Genes Progression Recurrence Study
APAF1 NA 0.05 Christoph et al, Int J Cancer, 2006
CDH13 0.00 0.01 Lin et al, Int Urol Nephrol, 2012
CDKN2A NA 0.05 Lin et al, Urol Oncol, 2010
DAPK1 NA 0.001 Tada et al, Cancer Res, 2002
DAPK1 NA 0.04 Christoph et al, Int J Cancer, 2006
IGFBP3 NA 0.02 Christoph et al, Int J Cancer, 2006
RASSF1A 0.004 NA Kim et al, Clin Genitourin Cancer, 2012
RASSF1A 0.04 NA Catto et al, J Clin Oncol, 2005
RASSF1A, CDH1, APC, TNFSR25, EDNRB 0.05 NA Yates et al, Clin Cancer Res, 2007
RUNX3 0.01 0.02 Kim et al, Cancer Res, 2005
RUNX3 0.006 0.04 Yan et al, J Surg Oncol, 2012
RUNX3 0.013 NA Kim et al, J Urol, 2008
SYMPO2 0.05 NA Cebrian et al, Cancer Res, 2008
SYMPO2 0.03 0.01 Alvarez-Mugica et al, J Urol, 2010
TBX2, TBX3, GATA2, ZIC4 0.003 NA Kandimalla et al, Eur Urol, 2012
TBX4 0.05 NA Reinert et al, Clin Cancer Res, 2011
TIMP3 NA 0.036 Friedrich et al, Eur J Cancer, 2005
TIMP3 0.01 NA Hoque et al, JNCI, 2006
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FGFR3-mutant and wild-type tumors. Finally, a few 
reports have also looked at histone methylation in 
NMIBC, and global H3K9 and H3K27 methylation 
has been shown to increase with progression from 
normal urothelium to NMIBC and MIBC. Further-
more, within NMIBC histone methylation levels 
correlate with increasing stage and grade.
In conclusion, DNA methylation is the most stud-
ied epigenetic modifi cation in bladder cancer. 
Unique methylation patterns distinguish between 
NMIBC and MIBC, as well as between FGFR3-
mutant and wild-type tumors. Epigenetic modifi ca-
tions can be used as biomarkers for bladder cancer 
detection, prognostication, and therapeutic benefi t 
prediction. Indeed, the analysis of methylated genes 
in urine represents an ideal tool for follow-up after 
TURBT, and DNA methylation and histone modifi -
cations might represent a potential target for future 
combination therapies in NMIUC.
INTRAVESICAL TARGETED GEN E 
THERAPY FOR LOW-GRADE (LG) NON 
MUSCLE-INVASIVE BLADDER CANCER 
(NMIBC)
Colin Dinney, M.D.
Several targetable “driver” mutations characterize 
low grade (LG) NMIBC. Leading the way are acti-
vating mutations and translocations of FGFR3, 
which are present in up to 70% of these tumors, 
while mutations in KDM6A, PIK3CA and HRAS 
are also relatively common. Multiple alterations are 
present in at least 25% of tumors, providing the 
opportunity to study their role in drug resistance [31, 
50]. Intravesical targeted gene therapy employing 
shRNA or full-length gene constructs is a promising 
approach to drug delivery that provides direct con-
tact between the vector carrying the therapeutic gene 
and the tumor. Reliable gene transfer to the urothe-
lium has been achieved and all targets are poten-
tially “druggable” by this approach, even if the ex-
act mechanism of action of the target gene is 
unknown [51]. Furthermore, while several of the 
available targeted agents have toxicity that pre-
cludes clinical development in LG NMIBC, intra-
vesical adenoviral and retroviral mediated gene 
therapy has been devoid of dose-limiting toxicity. 
Moreover tyrosine kinase inhibitors (TKIs) or anti-
bodies are not formulated for intravesical delivery 
and effective systemic delivery to the urothelium 
has not yet been demonstrated. 
Adenoviral mediated interferon-α gene therapy 
with the excipient Syn3 has demonstrated effi cacy 
in the “BCG Unresponsive” patient population [52], 
and the delivery of interferon-α in next generation 
lentiviruses promises to enhance gene delivery 
while minimizing random integration of viral DNA 
into the host genome. Interferon-α is also as a potent 
activator of PDL-1 and other immune modulators, 
so that adenoviral mediated interferon-α gene trans-
fer could also serve as an adjuvant to prime the 
immune system. Collaborations between academia 
and pharma are poised to explore intravesical adeno-
viral and lentiviral shFGFR3 and interferon-α gene 
therapy in immunocompetent animal models with 
the intent of rapid translation into clinical  trials.
OPEN DISCUSSION – TARGETS AND 
PATHWAYS FOR INTERVENTION
Moderator: Jonathan Rosenberg, M.D.
Following the presentation of pathways and tar-
gets, a robust discussion ensued reviewing potential 
drug targets. Currently, all therapies approved for 
treatment of NMIBC are delivered intravesically. 
This ensures high levels of drug are administered 
topically to the superfi cial tumors. The participants 
felt FGFR3 was the most relevant target given the 
high prevalence of activating mutations in this pa-
tient population. However, intravesical delivery of 
the current versions of FGFR3 inhibitors is unlikely 
to lead to sustained kinase inhibition of FGFR3 nec-
essary for anti-tumor activity. Discussion focused 
on the need for less toxic agents for systemic ad-
ministration for NMIBC, and potential ways to de-
liver a targeted agent intravesically. 
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SESSION II: CHECKPOINT 
BLOCKADE BIOLOGY, IDENTIFIED 
MECHANISMS AND THERAPIES 
RELEVANT TO BLADDER CANCER, 
AND CHALLENGES IN THE NON-
MUSCLE-INVASIVE DISEASE 
SETTING
Session Co-Chairs: Noah M. Hahn, M.D., Robert 
Svatek, M.D.
INTRODUCTION
Noah M. Hahn, M.D.
Simultan eous to the rapid articulation of specifi c 
targetable driver genetic alterations in bladder cancer 
through efforts such as the TCGA project, equally 
accelerated investigations of the molecular biology 
and candidate targets has occurred in the fi eld of 
immuno-oncology [5]. One of the earliest effective 
immunotherapies, intravesical BCG, has been em-
braced as a standard of care for NMIBC for over 
three decades [53, 54]. While effective at decreasing 
or delaying NMIBC relapses, the majority of patients 
treated with BCG do eventually develop recurrences. 
For BCG-unresponsive patients, cystectomy remains 
the standard of care in patients medically fi t for sur-
gery. While approaches such as high-dose interleu-
kin-2 have demonstrated the ability to cure a small 
subset of metastatic melanoma and renal cell carci-
noma patients, the intensity and morbidity associ-
ated with these initial immunotherapy efforts limited 
their applicability to larger populations, particularly 
patient groups such as NMIBC in which concurrent 
medical comorbidities are common [55-57].
In recent years though, the development and dem-
onstration of profound effi cacy with considerably 
more favorable side effect profi les of modern im-
munotherapy agents has quickly positioned immu-
notherapy as a critical approach to the therapy of 
multiple malignancies. Specifi cally, novel immune 
checkpoint inhibitors have been developed which 
block the cytotoxic T-lymphocyte–associated anti-
gen 4 (CTLA-4), programmed death-1 (PD-1) and 
programmed death-1 protein ligand (PD-L1) medi-
ated signaling [58, 59]. In normal physiology, the 
CTLA-4/PD-1/PD-L1 pathways function to dampen 
infl ammatory immune responses as a checkpoint 
balance preventing unregulated destructive infl am-
mation. In recently reported trials treating patients 
with metastatic urothelial cancer (UC) who have 
progressed after platinum based chemotherapy, re-
sponse rates doubling that seen traditionally with 
cytotoxic chemotherapy have been reported inde-
pendently for agents targeting both PD-1 and PD-L1 
with grade 3-4 toxicity rates of only 8-15% [36, 60]. 
In small studies in NMIBC patients at least 35% of 
patients demonstrated moderate or marked PD-1 
expression with an association noted between PD-1 
expression and prior BCG therapy [61]. Additional 
studies have demonstrated marked expression of 
PD-L1 among 69% of post-BCG relapsed UC tu-
mors compared to 19% of BCG-naïve tumors from 
the same patients [62]. Collectively, the data impli-
cates the PD-1/PD-L1 pathway as a potential key 
resistance mechanism to traditional BCG therapy. 
Agents targeting the CTLA-4/PD-1/PD-L1 path-
ways are now FDA approved for the treatment of 
metastatic melanoma and non-small cell lung cancer 
with approval in renal cell carcinoma expected soon. 
In addition, the safety and early effi cacy of other 
checkpoint inhibitor and agonist targets (LAG3, 
IDO1, GITR, 4-1BB, OX40, CD27, KIR2DL, CS-
F1R, CD40) is currently being evaluated in ongoing 
phase I trials. Collectively, the existing data and 
ongoing development efforts of additional check-
point inhibitors and agonists make modern immu-
notherapy agents an attractive therapeutic approach 
to investigate in NMIBC patients. The focus of 
CTPM session 2 was to leverage current immuno-
therapy clinical and translational data from bladder 
and other malignancies to produce optimal clinical 
trial designs to evaluate modern immunotherapy ap-
proaches in NMIBC patients. 
CHALLENGES OF THE NMIBC SPACE 
– ENDPOINTS , DRUG DELIVERY AND 
ACCRUAL
Prof. Dr. J. A. Witjes 
Currently, there  are still (too) many challenges or 
unmet needs in NMIBC therapy. Unfortunately, 
there are almost no new clinical developments since 
decades, probably because awareness (public, phar-
ma, funding) is limited and studies are challenging. 
The initial TUR is not radical in 20–30% of patients, 
and current adjuvant intravesical therapy reduces 
recurrence rates by no more than 50%. Guideline 
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recommendations are in part confl icting [63], and 
this might be one of the reasons that compliance to 
guidelines is far from optimal. An additional current 
problem is the shortage of the most effective intra-
vesical agent: BCG. Trial endpoints predominantly 
are tumor recurrence and progression. The impact 
on progression of currently used drug is controver-
sial and probably (very) limited [64]. Still, progres-
sion is an important endpoint with a life changing 
therapeutic alternative (radical cystectomy) and with 
a chance to develop lethal disease.
A potential new method to study drug effi cacy is 
a marker lesion study. The concept is that all but 
one bladder tumors is removed. The patient should 
have a history of low grade NMIBC since recur-
rences usually also are low grade. After 6 intra-
vesical instillations, for example, the effect on the 
marker lesion is evaluated after another few weeks. 
A complete response (CR) on cystoscopic evalua-
tion appears a pathological CR in >97%, making 
control biopsies in CR patients unnecessary. Twen-
ty-three such studies with >1200 patients have been 
done and reviewed [65]. Typically the marker lesion 
shows a CR in 30% to 50% of patients. For BCG 
these fi gures are 32%-61%, and the highest response 
rate was reported for Apaziquone (67%). In these 
>1200 patients progression was seen in 7 patients, 
however, these were initially all high risk. No pro-
gression in intermediate risk patients was seen. Pa-
tients with a CR also have a higher recurrence free 
survival, so the ablative effect seems to correlate 
with prophylactic effect.
In conclusion, there are still many unmet needs, 
and studies are challenging [66]. A potential alterna-
tive might be marker lesion studies, which are safe 
with a clear and rapid endpoint (3 months CR). For 
new drugs this means a short study duration with a 
limited number of patients. Last, but certainly not 
least, patients experience a limited burden and have 
a longer recurrence free survival when they experi-
ence a CR.
BIOLOGY/MECHANISMS OF CHECKPOINT 
INHIBITO RS
Arlene Sharpe, M.D., Ph.D.
It has long been known that tumors, including 
bladder cancer, are infi ltrated with CD8 (killer) T 
cells and that T cell infi ltration correlates in many 
cases with improved outcome [67]. What was less 
clear, however, were the mechanisms by which can-
cers continued to progress, despite dense T cell in-
fi ltration. More recent data show that multiple in-
hibitory pathways dampen an anti-tumor T cell 
response; and the interactions between immune 
checkpoint molecules on tumor-infi ltrating lympho-
cytes and their ligands on tumor cells or intra-tumor-
al myeloid cells represent druggable targets for re-
invigorating an anti-tumor response [68]. Among the 
multiple immune checkpoints under study, that medi-
ated by the interaction between PD-1 and its ligands 
PD-L1 and/or PD-L2 has risen to the forefront of 
clinical investigation; as antibody-mediated block-
Fig. 5. Mechanism of Action of PD-1 or PD-L1 Blockade.
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ade of either PD-1 or PD-L1 induces objective re-
sponses in a number of tumor types [69]. PD-1 (Pro-
grammed Death 1) is expressed on activated T cells, 
as well as on T cells that have become functionally 
exhausted due to chronic antigen exposure, and is 
highly expressed on CD8 tumor infi ltrating cells 
(TIL) in most tumor types (Fig. 5). The signal trans-
mitted when PD-L1 or PD-L2 binds to PD-1 inhibits 
many aspects of T cell function, including cytokine 
production and perhaps most distressingly, the abil-
ity of CD8 T cells to lyse their tumor targets. While 
PD-1 is broadly expressed on tumor infi ltrating lym-
phocytes, expression of the PD-1 ligands appears to 
be more tightly controlled, and probably evolved to 
protect normal tissues from CD8-mediated attack 
during infl ammation or wound healing. In that re-
gard, PD-L1 expression can be strongly up-regulated 
by pro-infl ammatory cytokines secreted from T cells, 
most notably interferon gamma. Indeed, in some tu-
mor types, PD-L1 expression on tumor cells seems 
to be strongly co-localized with infi ltrating CD8 T 
cells [70]. These data also lead to the concept that 
tumors with clear CD8 infi ltration and PD-L1 ex-
pression should be more likely to respond to anti-
body-mediated blockade of either PD-1 or PD-L1, a 
concept that is fairly well-supported in UBC [36], 
although there is a signifi cant fraction of PD-L1 
‘negative’ patients that show evidence of clinical 
responses. In addition the PD-1/PD-L1 axis, there 
are a number of additional immune checkpoints that 
can be expressed on tumor infi ltrating lymphocytes; 
these include LAG-3, TIM-3, TIGIT and several oth-
ers. Pre-clinical and clinical data suggest that check-
point mediated inhibition of T cell function likely 
involves multiple non-overlapping pathways [71], 
suggesting that, for maximal clinical effi cacy, mul-
tiple immune checkpoints may need to be blocked 
in parallel, as recently shown in melanoma [72], kid-
ney cancer [73] and several other tumor types.
MONO VS. DUAL THERAPY FROM OTHER 
CANCERS
C harles Drake, M.D., Ph.D.
Although PD-1/PD-L1 blockade has clear activ-
ity in multiple tumor types; as discussed above it 
has become increasingly clear that multiple immune 
mechanisms serve to dampen anti-tumor T cell re-
sponses in patients [74]. Clinically, this is important 
because the all-comers response rate to PD-1/PD-L1 
blockade is in the 20-25% range in several tumor 
types, and for PD-L1 blockade it is likely in the 15% 
range in urinary bladder cancer (Hoffman-Censtis, 
unpublished). Thus, combining PD-1/PD-L1 block-
ade with additional modalities may be important in 
increasing both the long term response rate as well 
as the frequency with which responses occur. The 
most compelling clinical data regarding combina-
tion immunotherapy come from trials in which PD-1 
blockade is combined with CTLA-4 blockade; this 
combination was recently FDA-approved in mela-
noma [72], and has shown impressive activity in 
renal cell carcinoma (RCC) and lung cancer as well. 
Mechanistically, synergy between PD-1/PD-L1 
blockade and CTLA-4 blockade likely occurs be-
cause CTLA-4 is highly expressed on the regula-
tory T cells that infi ltrate tumors [75], so these two 
may agents target CD8 TIL and CD4 tumor infi ltrat-
ing regulatory T cells, respectively. Although gener-
ally tolerable, combined CTLA-4/PD-1 blockade is 
associated with a high rate of Grade III and IV im-
mune related adverse events; these events necessi-
tate intervention with corticosteroids and occasion-
ally with drugs that block tumor necrosis factor 
(TNF) [76]. While such combinations are clearly 
warranted in advanced cancer patients, their applica-
tion to patients with NMIBC may be harder to jus-
tify. Other immune/immune combinations may 
prove more tolerable, such as the combined block-
ade of PD-1 and the immune checkpoint mediated 
by the interaction between LAG-3 and Class II 
MHC [77], an anti-LAG-3 antibody is now in a 
Phase I combination trial (NCT01968109).
Because PD-1/PD-L1 blockade is generally well-
tolerated, and has a reasonable response rate, this 
intervention is often proposed as a backbone for 
combination regimens. In addition to immune 
checkpoint molecules, there are also a series of mol-
ecules expressed on either T cells or on other im-
mune cells in the tumor microenvironment that pro-
mote immune activation (rather than repression). 
Examples include OX40 (expressed on T cells), 
41BB (also expressed on T cells) and CD40, which 
is expressed on antigen-presenting cells and B cells. 
To target these pathways, agonist antibodies have 
been developed, and are in Phase I trials either alone 
or in combination with PD-1 blockade in several 
tumor types [78]. To date, however, the combination 
of an immune checkpoint and an immune agonist 
has not been comprehensively tested in either 
NMIBC or in muscle invasive or metastatic urothe-
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lial cancer. A second potential  combination strategy 
involves the pairing of PD-1/PD-L1 blocking agents 
with conventional therapies like chemotherapy or 
radiation therapy (discussed below). Combining im-
munotherapy with chemotherapy can be challeng-
ing; most preclinical studies support the notion that 
only certain chemotherapy agents have immune-
enhancing effects and that dose and sequencing may 
be critical [79]. With a few notable exceptions [80], 
those lessons have largely been ignored in the clin-
ic, where immune checkpoint blockade is often 
blindly added to conventional, full-dose chemother-
apy. A fi nal combination of note involves co-admin-
istering immune checkpoint blocking reagents with 
anti-angiogenic therapies; this combination is based 
on data showing that tumor-infi ltrating blood vessels 
are disordered and represent a challenge to T cell 
egress. Normalizing the tumor vasculature with 
anti-VEGF targeted antibodies may facilitate tumor 
infi ltration with T cells, and be synergistic with im-
mune checkpoint blockade. Preliminary data sug-
gest activity for the combination of anti-VEGF 
(Bevicizumab) and anti-PD-L1 (Atezolizumab) in 
RCC, with an interesting Phase II trial in 
(NCT01984242) now fully accrued. So, taken to-
gether, both preclinical and clinical data support the 
notion that combined immune checkpoint blockade 
may be required to induce durable and/or complete 
responses in the majority of NMIBC patients, but 
also highlight the fact that the ever expanding num-
ber of potential combinations means that clinical 
evaluation could prove challenging. 
RADIATION INDUCED IMMUNE 
RESPONS ES
Andrew Sharabi, M.D., Ph.D.
Recently, checkpoint blockade immunotherapy 
(CBI) has been reported to have notable activity in 
metastatic bladder cancer and is establishing itself 
as a fourth pillar of cancer care. A current focus is 
understanding how to best incorporate immuno-
therapy into defi nitive and palliative treatment 
regimens involving surgery, chemotherapy, and ra-
diation. Interestingly, there is now an established 
body of pre-clinical literature and emerging clinical 
data demonstrating that radiation can modify im-
mune responses [81]. Given the known effi cacy of 
radiation in muscle invasive bladder cancer, this 
raises the question of whether radiation combined 
with immunotherapy could be used in earlier stag-
es of disease including the non-muscle invasive 
setting. 
Our group has been investigating the effects of 
combining stereotactic radiation with anti-PD-1 
checkpoint blockade immunotherapy in a number of 
pre-clinical models [82]. We have identifi ed that 
radiation can synergize with immunotherapy spe-
cifi cally by causing infl ammatory cell death and 
release of tumor antigens which are cross-presented 
in the draining lymph node [82]. This increase in 
antigen presentation drives the activation and pro-
liferation of tumor specifi c cytotoxic T-cells. At the 
same time we have demonstrated that radiation 
Fig. 6. Radiation combined wit h anti-PD-1 immunotherapy improves local tumor control (A) and development 
of systemic anti-tumor immune response (B)[82]. 
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modulates the tumor microenvironment and enhanc-
es T-cell infi ltration into tumors while simultane-
ously causing the tumor cells to become more sus-
ceptible to immune mediated cell death [82]. These 
data suggest that radiation may be an ideal modal-
ity to combine with immunotherapy (Fig. 6). Given 
these fi ndings we have proposed that a low dose of 
radiation (8Gyx1 or 6Gyx3) could be combined with 
checkpoint blockade immunotherapy in BCG unre-
sponsive non-muscle invasive bladder cancer. The 
aim of this experimental treatment arm would be to 
evaluate whether radiation combined with anti-PD-1 
immunotherapy improves local tumor control and 
development of systemic anti-tumor immune re-
sponses compared to anti-PD-1 immunotherapy 
alone. There are limited treatment options in this 
setting and this data would shed light on a potential 
novel therapeutic modality for non-muscle invasive 
bladder cancer.
INTEGRATING PATHOLOGY INTO NMIBC 
 DRUG DEVELOPMENT: COMPANION 
DIAGNOSTICS, NEOANTIGENS, AND 
T-CELL REARRANGEMENTS
Margaret Callahan, M.D., Ph.D.
There is a signifi cant unmet need for companion 
diagnostic tests that help select patients that are most 
likely, or unlikely, to benefi t from immunotherapy. 
As of the date of this meeting in March of 2015, a 
spectrum of potential biomarkers have been ex-
plored, primarily in small, single-institution, retro-
spective studies, however, no validated biomarker 
is in clinical use. In this session, we outlined the 
rationale, clinically desirable characteristics, and 
preliminary research on biomarkers in this area. 
Immunotherapy has been an area of signifi cant 
excitement and interest, especially with the growing 
appreciation for the activity of PD-1 and PD-L1 
blockade in the diversity of cancer types, including 
bladder cancer. However, in most clinical scenarios, 
only a minority of patients benefi t from immuno-
therapy treatment and responses are sometimes slow 
to develop, underscoring the utility that a predictive 
biomarker could play in guiding treatment choices. 
An ideal biomarker for this fi eld would be present 
prior to initiation of treatment, or early enough in 
treatment to shape clinical decision-making. More-
over, this ideal biomarker would predict clinically 
relevant outcomes (response, survival, toxicity) with 
specifi city and sensitivity. Lastly, this hypothetical 
biomarker would be an assay that would be feasible 
to perform on clinical samples (rapid results, with-
out undue complexity, reproducible and robust). 
Strategies for correlative analyses of human sam-
ples in patients treated with immunotherapy has 
comprised investigation of peripheral blood cells, 
serum or plasma, tumor microenvironment and 
other tissues. Tools have included fl ow cytometry, 
DNA and RNA sequence analysis, serology, immu-
nohistochemistry and others. We reviewed data on 
peripheral blood correlates that have been investi-
gated in patients with melanoma that have been 
treated with CTLA-4 blocking antibodies, including 
absolute lymphocyte count (ALC), myeloid derived 
suppressor cells (MDSC) and changes in pheno-
typic markers on peripheral T cells like ki67 [83–
89]. We also briefl y reviewed recent publications on 
the role that T cell receptor diversity may play in 
patients treated with PD-1 or CTLA-4 blocking an-
tibodies [38, 90, 91]. We reviewed the abundant data 
of PD-L1 expression in the tumor microenvironment 
and its link to favorable clinical outcomes for patient 
treated with PD-1 or PD-L1 blocking antibodies 
across a diversity of tumor types [59, 92, 93]. It was 
noted, however, that most studies found that at least 
some patients whose tumors tested negative for PD-
L1 had responses to these agents, and therefore, the 
specifi city of this assay may not be suffi cient for 
selection of patients. Lastly, we discussed emerging 
data on how the burden of random tumor mutations 
may infl uence the immune system and responses to 
immunotherapy [94–96].
DEFINITIONS AND ENDPOINTS IN 
THE  NMIBC ARENA: PERSPECTIVE OF 
CLINICAL TRIALS
Ashish Kamat, M.D., MBBS, FACS
There is a signifi cant unmet need for new thera-
pies in NMIBC. Studies in this area have lagged 
behind due to lack of consensus on trial endpoints 
and appropriate control arms which handicaps regu-
latory bodies, investigators and results in confusion 
due to perceived diffi culties related to these factors. 
In recent years, the International Bladder Cancer 
Group (IBCG), American Urological Association 
(AUA), FDA, European Association of Urology 
(EAU) and others to have tried to address these is-
sues and propose trial designs to support the devel-
opment of new therapies for NMIBC [63, 97]. The 
purpose of this discussion was to expand upon this 
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work and provide recommendations on appropriate 
clinical trial designs in NMIBC based on evidence-
based literature, current clinical practice guidelines 
and expert consensus [98].
It must be fi rst recognized that the design of clin-
ical trials in NMIBC should be such that they pro-
vide the most clinically relevant data for the spe-
cifi c risk category of interest (low, intermediate or 
high). Thus, the risk classifi cation is of paramount 
importance. To summarize: Low Risk Category is 
those tumors that are solitary, primary, Ta low grade 
tumors that are < 3 cm in size; the High Risk Cat-
egory include any T1 or high grade Ta, including 
CIS and Intermediate Risk tumors include every-
thing else (i.e. recurrent/multiple TaLG tumors) [99]. 
Next, the patient population must be stratifi ed 
based on prior exposure to immunotherapy with 
BCG. For trials examining the BCG-failure popula-
tion, the BCG induction and maintenance schedule 
administered prior to failure and the type of failure 
(BCG unresponsive, refractory, relapsing, or intoler-
ant) should be clearly outlined to make comparisons 
across trials feasible [100]. While BCG failure has 
been broadly defi ned as any recurrence or progres-
sion during therapy, this term is quite heterogeneous, 
and comparing salvage therapies in this population, 
hindered by the lack of standard defi nitions, incon-
sistent methods of reporting results does not provide 
meaningful data. The timing of therapy assessment 
is also important – it must be remembered that we 
need to wait until the 6-month evaluation time point 
to identify high-risk NMIBC as truly BCG refrac-
tory since an additional 25-67% who do not respond 
to an initial induction course, will respond to a sec-
ond course of BCG. Also, it must be emphasized 
that recurrence of tumor after inadequate BCG does 
not carry the same prognostic implication to the 
patient as it does when tumor recurs after adequate 
BCG therapy. The term ‘BCG unresponsive’ which 
essentially includes ‘BCG refractory’ and ‘BCG re-
lapsing’ (within 6 months of last BCG exposure) 
patients is a new term meant to denote a subgroup 
of patients at highest risk of recurrence and progres-
sion for whom additional BCG therapy is not a fea-
sible option [101]. These patients can be considered 
for single arm studies. However, it is imperative that 
all subjects enrolled in trials of novel therapeutics 
after adequate BCG (defi ned as induction BCG with 
6 weekly instillations and at least 1 maintenance 
course) be informed that treatments other than cys-
tectomy in this population are considered oncologi-
cally inferior at present.
In general, randomized superiority trial designs 
are recommended for most risk levels. Since non-
inferiority trials often require a large sample size, 
they should be used sparingly. Placebo control is 
considered unethical for all intermediate- and high-
risk strata; therefore, control arms should comprise 
the current guideline-recommended standard of care 
for the respective risk level. Realistic effi cacy 
thresholds should be set to ensure that novel thera-
pies receive due review by regulatory bodies – for 
example, in patients with low risk disease, an ab-
solute reduction of 6% in the percent of patients 
with recurrence at 2 years would be a reasonable 
magnitude of effect for a clinical trial to be consid-
ered ‘positive’ since this would be actually a relative 
risk reduction of over 40% due to low incident 
events. One the other hand, for patients in the BCG 
unresponsive category, where much more is at stake 
and event rates are higher, a clinically meaningful 
initial CR rate (for CIS) or recurrence-free rate (for 
papillary tumors) of at least 50% at 6 months, 30% 
at 12 months and 25% at 18 months is recommend-
ed. This is in agreement with the report from the 
AUA/FDA workshop where it was suggested that 
the effi cacy be set such that the lower bound 95% 
CI excludes 20% (albeit at a longer time duration) 
[2].
OPEN DISCUSSION – CHECKPOINT 
BLOC KADE AND IMMUNOTHERAPY 
INTERVENTIONS
Moderator: Noah M. Hahn, M.D.
Following the aforementioned presentations by 
leading experts in the fi elds of immunotherapy and 
NMIBC clinical trial designs, a robust discussion 
ensued with engaging dialogue amongst urology, 
oncology, radiation oncology, pathology, immuno-
oncology, and biostatistics investigators in atten-
dance. Points of deeper discussion included: 
1.  Analysis of optimal NMIBC populations for 
multi-institution academic and industry clinical 
trial collaborations.
2.  Review of the new defi nitions of BCG-unrespon-
sive vs. BCG-relapsing NMIBC populations and 
their impact on accrual expectations.
3.  Appropriate clinical trial endpoints in NMIBC 
populations particularly papillary (Ta/T1) com-
pared to CIS-only disease.
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4.  Investigator comfort level with enrolling NMIBC 
patients to immunotherapy clinical trials given 
the currently available toxicity data from meta-
static cancer patients.
5.  Presentation of candidate clinical trial concepts 
for feedback from the group.
REGULATORY SESSION
REGISTRATION O F THERAPY FOR NON-
M USCLE INVASIVE BLADDER CANCER
Jonathan Jarow, M.D. 
The following comments are thoughts about the 
design of clinical trials with a regulatory intent for 
the development of products used to treat NMIBC. 
As a general rule, randomized clinical trials using a 
time-to-event endpoint are strongly preferred for 
oncology indications. The comparator may be pla-
cebo, when ethical and/or feasible, or an active con-
trol for a superiority trial. Non-inferiority trial design 
is acceptable against an approved agent as long as 
a meaningful inferiority margin can be identifi ed and 
assay sensitivity is assured. The lack of contempo-
rary placebo-controlled trials of BCG makes it dif-
fi cult to determine inferiority margins for a time-to-
event, recurrence-free survival, non-inferiority trial 
against BCG. Trials that include patients with pure 
papillary disease should use recurrence-free sur-
vival as the primary endpoint. Events include any 
recurrence within the bladder or prostatic urethra. 
Upper tract disease is not normally counted as events 
in the primary analysis for intravesical therapies but 
should be counted as events for trials of systemic 
therapies. A sensitivity analysis will be performed 
including/excluding these events. Disease-free sur-
vival is the preferred primary endpoint for trials that 
include a mix of patients with papillary disease with 
or without CIS. Events are dated to the time of recur-
rence and time zero for failure to achieve a complete 
response for those patients with CIS at enrollment.
Patients with high-risk disease following treat-
ment with BCG have been the preferred population 
to study new therapies for NMIBC. For a variety of 
practical reasons, it has been extremely hard for 
commercial sponsors to successfully conduct a ran-
domized controlled trial in this population. FDA 
encourages the use of the IBCG and Society for 
Urologic Oncology (SUO) defi nition for the “BCG-
unresponsive” population for the enrollment criteria 
for these trials [3, 102]. Patients with BCG-unre-
sponsive CIS go on to cystectomy in the absence of 
complete response. Thus, a complete response rate 
of suffi cient magnitude and duration is clinically 
meaningful in this patient population. A single-arm 
trial is acceptable in this setting because the natural 
history of this disease is well characterized and we 
would not expect spontaneous resolution. Neverthe-
less, there are alternative approaches for testing a 
new drug in a randomized control trial either as an 
add-on therapy to BCG (against placebo) or in a 
lower risk stratum against either placebo or another 
active agent. 
SESSION III: CLINICAL 
TRIAL DESIGNS, T UMOR 
ACQUISITION, EMBEDDED 
COMPANION DIAGNOSTICS, AND 
TRIAL REQUIREMENTS AND 
INFRASTRUCTURE CHALLENGES 
UNIQUE TO CLINICAL TRIALS IN 
NMIBC
Session Co-Chairs: Michael O’Donnell, M.D., 
 Susan Groshen, Ph.D., Donna Hansel, M.D., Ph.D.
INTRODUCTION
Michael O’Donnell, M.D.
W hen it comes to clinical trials in general and 
NMIBC clinical trials in particular, the devil is in 
the details. Beginning with patient considerations, 
even the most well designed clinical trial will fail 
if recruitment is undermined by a perceived burden-
some protocol or unclear patient-oriented benefi t/
risk ratio. Given the extremes of risk between un-
treated low-grade disease and heavily pretreated 
patients with high-grade disease, for instance, nu-
merical abundance in the former may be offset by 
convenience of conventional therapy while the rare 
but motivated patient in the latter clamoring for 
novel treatment my be dissuaded by the worry of 
progression or need to travel long distances. Careful 
attention to the nuances in each subcategory of 
NMIBC is thus essential to success. 
Clinical trial endpoints also vary with the popula-
tion chosen. Thus, use of complete response rate is 
only valid for CIS or marker lesions where disease 
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is unequivocally present at study onset. Disease-free 
survival (DFS) on the other hand may be necessary 
for patients with resected papillary patients at risk 
for recurrence. Trials including mixtures of CIS and 
papillary patients would therefore be troublesome 
for fi nding a common endpoint. Furthermore, how 
and when does one defi ne the clinical meaningful-
ness of the endpoints selected? Even endpoints of 
progression and survival are problematic given 
dropout, subjective decisions for cystectomy and 
competing causes for death, for instance. Further-
more, the whole traditional cumbersome Phase I, II, 
and III trial architecture for getting drug approval is 
becoming archaic in the emerging demand for bring-
ing new agents to market sooner and proliferation 
of multiple potential candidates.
Even bladder tissue histology and cytology are 
not without major considerations, as inter- and intra-
observer variability make even referee pathologic 
verifi cation problematic. Once tissue acquisition for 
correlative studies is required, a whole new set of 
issues arises including harvest (frozen or paraffi n), 
transport, storage and even reproducible analysis. In 
certain cases, such as CIS, there may not even be 
suffi cient tissue for anything but the most basic of 
studies. This may be especially relevant for new 
checkpoint inhibitors that have an associated com-
panion diagnostic for patient selection. Similarly, 
liquid biospecimens, such as urine and blood, pres-
ent new challenges not only in logistics and infra-
structure but also in quality control. Furthermore, 
specimen prioritization for competing correlative 
studies becomes a matter in and of itself. 
The sections that follow will delve into the nu-
ances in all of these logistical matters in clinical 
trials of NMIBC. While not all the answers are avail-
able, at least a clearer understanding of the diffi cul-
ties and challenges will be provided.
PATIENT ADVOCATE PERSPECTIVES ON 
CLINIC AL TRIAL DESIGN
Diane Zipursky Quale, J.D. 
Patient recruitment and retention are signifi cant 
challenges to the success of all types of clinical tri-
als. The primary motivation for a patient to partici-
pate in a trial is personal: What’s in it for me? How 
will participation in the trial improve my prognosis? 
To improve recruitment for NMIBC, efforts must be 
directed at dispelling the myth that clinical trials are 
only for patients with advanced disease who have 
no other treatment options. A trial that is designed 
to prevent recurrence or progression of disease rep-
resents a tangible benefi t to the patient. However, if 
the trial requires additional cystoscopies beyond the 
standard of care, or involves systemic chemothera-
py, which is not part of the standard of care, the 
benefi t to participation may be greatly offset. A 
marker lesion trial presents signifi cant recruitment 
challenges, as most patients are anxious to have their 
tumors removed as soon as possible. To attract a 
patient to this type of trial, the physician must min-
imize any possible risk of progression of the disease 
during the time the marker lesion remains in place.
Patients will travel for a perceived benefi t to 
clinical trial participation, but important consider-
ations are distance, number of visits required and 
length of visit, and whether the trial center can offer 
any resources to assist with travel time and expenses. 
Well designed and thoughtful educational and 
awareness tools are essential to ensuring rapid and 
full clinical trial enrollment. Patient advocacy orga-
nizations such as the Bladder Cancer Advocacy 
Network can assist in providing patient-focused in-
put on educational materials for specifi c clinical tri-
als, and can also provide outreach to the bladder 
cancer patient community through educational fo-
rums and social media to raise the awareness and 
understanding of clinical trials [103]. 
CLINICAL TRIAL DESIGNS AND 
ENDPOINTS FO R NMIBC TRIALS
Catherine M. Tangen, Dr.P.H.
The Southwest Oncology Group (SWOG) has 
experience enrolling NMIBC patients on their clin-
ical trials. SWOG successfully completed accrual to 
a non-intergroup randomized phase III trial of new-
ly diagnosed or recurrent Grade 1-2, Ta or T1 tran-
sitional cell carcinoma (S0337, NCT00445601), 
averaging 7 patients per month. In the BCG refrac-
tory population, SWOG completed a phase II trial 
averaging two patients per month (S0353)[104]. 
With respect to endpoint experience, SWOG’s prior 
phase III randomized BCG maintenance trial 
(S8507)[100] explored the composite endpoint of 
worsening-free survival which was defi ned as the 
fi rst evidence of: biopsy proven ≥ T2 disease (17% 
of events), initiation of system chemotherapy or ra-
diation (3%), cystectomy (9%), or death due to any 
cause (74% of events) (Fig. 7). If we had restricted 
death to only bladder cancer deaths, only one-third 
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of deaths would have been counted as related to 
bladder cancer. Obtaining complete and reliable sub-
sequent treatment information and cause-of-death 
for patients enrolled in a large intergroup trial many 
years after randomization can be challenging.
Targeted (“bucket” or “basket”) design trials[105] 
can be conducted in the discovery phase where a 
number of sub-studies are placed under one um-
brella with a common platform for evaluating tissue 
marker status. A patient is assigned to a sub-study 
and single-arm targeted agent based on his/her bio-
marker status, and the primary objective is an initial 
assessment of clinical activity in the specifi c popu-
lation. For these trials, reliable marker-specifi c his-
torical data are needed in order to pre-specify the 
level of response activity that would be of interest 
to pursue in subsequent studies. In contrast, a con-
fi rmatory targeted design will include a mix of ran-
domized sub-studies. Patients are randomized be-
tween a standard and targeted treatment where the 
standard arm may be the same across the sub-stud-
ies, or study specifi c. As in the discovery targeted 
design, patients are assigned to a sub-study based 
on marker status. The sub-study can be a random-
ized phase II or a phase II/III trial where arms that 
show lack of activity at a planned interim analysis 
are dropped. If there is a lack of evidence about 
marker specifi city for a treatment, allow all-comers 
to enroll and stratify on marker status and increase 
the sample size as needed to allow for some assess-
ment of the marker by treatment interaction. If the 
goal is to screen a number of regimens that are not 
necessarily marker-targeted, then using a selection 
design [106, 107] or randomized phase II/III [108, 
109] with multiple arms may be a good strategy.
THE PATHOLOGIST PERSPECTIVE IN 
TISSUE ACQU ISITION AND ANALYSIS
Donna Hansel, M.D., Ph.D.
The central role that pathologists play in su-
ccessful clinical trials design, implementation and 
 correlative study completion cannot be over-
emphasized. As pathology has moved toward sub-
specialization in most major medical institutions in 
the United States, the detail of pathological diagno-
ses has also expanded in line with medical treatment 
parameters. Several studies have now demonstrated 
signifi cant diagnostic changes in urologic pathology 
specimens when re-reviewed by a subspecialist 
[110], highlighting the critical need for advanced 
training. Subtyping of cancers to identify those that 
harbor distinct molecular and/or morphological fea-
tures associated with behavior or response to drug 
therapy is also becoming mainstream practice, with 
many sites expanding in-house genomic test panels. 
The combination of accurate diagnostic reads and 
availability of molecular testing are two crucial pa-
rameters in the design and successful implementa-
tion of emerging clinical trials. In the fi eld of bladder 
cancer, rapidly changing subclassifi cations of in situ 
and invasive disease, limitations in diagnosis by 
Fig. 7. Time to Worsening Event Stratifi ed by Maintenance BCG
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specimen type, and quantifi cation of tumor volume 
can all impact enrollment criteria. 
In conjunction with the clinical parameters as-
sociated with pathology review, most pathology 
departments are engaged in biorepository efforts 
that directly impact the collection of tissue and the 
application of correlative biomarkers associated 
with clinical trials efforts. Several standard guide-
lines around best practices have emerged and are 
publicly available [111]. Biobanking of tissue, urine 
and blood are routinely performed, with quality met-
rics that include percent tumor nuclei, percent ne-
crosis, and morphology of harvested lesion. In 
NMIBC clinical trials, many specimens will include 
transurethral resection (TUR) specimens that are 
routinely fully submitted for formalin-fi xed, paraf-
fi n-embedded (FFPE) material. However, consented 
protocols in which a portion is submitted for frozen 
storage with concurrent diagnostic frozen slide prep-
aration can expand the use of this tissue without 
compromising patient care. The volume and type of 
materials available, whether FFPE or frozen, sig-
nifi cantly impacts the type of correlative studies that 
can be performed as part of a clinical trial. In 
NMIBC studies, the majority of specimens will in-
clude FFPE biopsy and TUR material, with a more 
limited portion of TUR material frozen for larger 
cancer specimens. Use of FFPE material has been 
routinely used for histological and immunohisto-
chemical analysis, with more recent inclusion of this 
material for whole exome sequencing. Whereas 
RNA-based analysis on FFPE material has im-
proved, many studies still prefer frozen tissue for 
these applications. Given that the correlative end-
points of clinical trials are decided during the design 
phase of clinical trials, involvement of pathologists 
to discuss the volume of materials available and the 
types of testing possible, can signifi cantly improve 
the successful completion of correlative studies.
PDL1 AS A BIOMARKER IN CLINICAL 
TRIALS OF  CHECKPOINT INHIBITORS IN 
BLADDER CANCER AND OTHER SOLID 
TUMORS
Andrea B. Apolo, M.D.
Immunotherapy with immune checkpoint inhibi-
tors is now an established treatment modality in 
cancer therapy. Agents are in rapid development by 
pharmaceutical companies (Merck, Bristol-Myers 
Squibb, Merck Serono, Metaimmune/AstraZeneca, 
Macrogenics, and Genentech) in multiple tumor 
types, including bladder cancer. Many bladder can-
cer clinical trials are in development or are ongoing 
in all disease states (non-muscle-invasive, muscle-
invasive, and advanced refractory metastatic disease 
in the fi rst-line cisplatin-ineligible and second-line 
setting and beyond). This has created a growing 
demand for predictive biomarkers to assist in select-
ing patients who would most benefi t from these 
therapies. PD-L1 expression by immunohistochem-
istry (IHC) on tumors or in tumor-infi ltrating im-
mune cells is being developed as a companion assay. 
Many clinical trials have demonstrated that patients 
positive for PD-L1 expression have a higher radio-
logic response to anti-PD-1 or PD-L1 therapy [36, 
37, 59, 112–117] compared to those who are PD-L1-
negative. Response to PD-1/PD-L1 inhibitors is not 
limited to patients with PD-L1-positive tumors or 
tumor-infi ltrating immune cells. Patients who do not 
express PD-L1 may still have radiologic tumor 
shrinkage and durable responses, although to a less-
Table 6
Selected assays for immunohistochemistry assessment of PD-L1 status 
(reprinted with permission from Apolo AB, 2016, Eur Urol Focus 1:269-271, Elsevier Ltd.) [122].
Source Monoclonal 
antibody
Clone Automated Cells evaluated Staining 
location
Positive Cutoff
Genentech/
Rochea [37] 
Rabbit SP142 Yes Tumor cell and tumor-
infi ltrating immune cells 
Membrane IHC 0b <1%
IHC1b ≥1% to ≤5%
IHC2 ≥5% to ≤10% 
IHC3 ≥10% 
Merck Murine 22C3 Yes Tumor cell and tumor-
infi ltrating immune cells 
Membrane ≥1% 
Bristol-Myers 
Squibb [118] 
Rabbit 28-8 Yes Tumor cell Membrane ≥5%
Hopkins Murine 5H1 No Tumor cell Membrane ≥5% 
a Commercially available b IHC 0/1 are considered negative
IHC = immunohistochemistry
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er degree. Therefore, PD-L1 expression status can-
not be used as a biomarker for patient selection for 
treatment with PD-1/PD-L1 inhibitors, except in the 
context of a clinical trial. However, PD-L1 status 
seems to be less relevant in combination studies 
[118]. This is a very important factor since many 
clinical trials of PD-1/PD-L1 inhibitors currently in 
development are in combination with chemotherapy, 
radiation, tyrosine kinase inhibitors, and other im-
munotherapies. The hypothesis is that many of these 
agents have immunomodulatory properties, such as 
inhibiting tumor-induced immunosuppressive 
mechanisms and increasing direct or indirect stimu-
latory effects on immune effector molecules [118–
121], which may prime the tumor and enhance the 
immune system. Studies have shown that PD-L1 
expression on tumor-infi ltrating immune cells and 
tumor cells can increase in patients treated with 
PD-1/PD-L1 inhibitors [37], supporting the theory 
that PD-L1 tumor status is dynamic. Therefore, pre-
treatment PD-L1 status may not accurately refl ect 
the tumor microenvironment and potential immune 
response to these therapies.
Another major issue in categorizing patients by 
PD-L1 status is the large variability in assays and 
interpretation of PD-L1 IHC staining (Table 6) 
[122]. Of the many PD-L1 antibody assays, some 
measure PD-L1 in the tumor, some measure PD-L1 
in immune-infi ltrating cells, and some measure both. 
Nor do the assays use common cutoffs for positiv-
ity. This lack of standardization among assays under 
development, along with a lack of comparative data 
among assays, is among the limitations of using 
PD-L1 IHC status to categorize patients.
TOXICITY OF IMMUNE CHECKPOINT IN-
HIBITORS
The toxicity profi le for PD-1/PD-L1 inhibitors is 
favorable compared to standard cytotoxic treat-
ments. Grade ≥ 3 toxicities (mainly in the skin, 
liver, and kidneys) range from 5% to 55% in solid 
tumor clinical trials and 4% to 16% in the two blad-
der cancer trials reported to date [36, 123, 124]. 
Furthermore, these agents may produce rare bu t se-
rious immune-mediated toxicities such as rhabdo-
myolysis, neuromyopathy, and toxic encephalopa-
thy [123]. Patients with non-muscle-invasive bladder 
cancer who have a good prognosis will be less tol-
erant of these toxicities than patients with advanced 
incurable metastatic bladder cancer.
THE CORRELATIVES C HALLENGES –E.G., 
EMBEDDED STUDIES OF MECHANISMS 
OF RESPONSE/RESISTANCE; VALIDATING 
GENETIC TARGETS
Joaquim Bellmunt, M.D., Ph.D.
The overarching principle of precision medicine 
in urothelial cancer treatment is the coupling of mo-
lecular, genomic, and clinic-pathologic prognostic 
factors with therapeutics to optimize the effective 
anticancer strategies. 
With the advent of the new checkpoint inhibitors 
that are changing the treatment landscape in bladder 
cancer, more creative and innovative strategies are 
clearly required. Trial strategies with incorporation 
of predictive biomarkers of response related to the 
tumor itself and to the tumor microenvironment 
need to be fully understood. New technological and 
computational analyses are now being implemented 
to uncover the predictive biomarkers of response 
and resistance in clinical trials of targeted therapies 
and immunotherapy. 
Many centers are now routinely molecularly char-
acterizing bladder cancer with either whole genome 
or whole exome sequencing or targeted sequencing 
of mutational hotspots for patients referred for ge-
nomically driven clinical trials. However, limita-
tions are the low frequency of relatively rare targe-
table genomic alterations. Trial enrollment for a 
single tumor and molecular subtype may be chal-
lenging. This has led to the development of um-
brella and basket trials implemented now in bladder 
cancer. Limitations of personalized treatments in 
genomically driven trials are the intratumoral het-
erogeneity and the limitations on obtaining multiple 
tumor biopsies at sequential time points. Cell-free 
DNA now in its infancy, may help to adequately 
provide timely information on the mechanisms of 
response and resistance. 
One of the benefi ts of incorporating biomarker 
enrichment strategies earlier in clinical trials is that 
it allows for the continuous refi nement of technolo-
gies. For the checkpoint inhibitor trials, programmed 
death-ligand 1 (PD-L1) expression has emerged as 
a potential predictive biomarker for PD-1-directed 
therapy. While PD-L1 staining on immune and tu-
mor cells correlates with response, the positive pre-
dictive value of these biomarkers is insuffi cient for 
routine clinical use. Several studies have presented 
now additional hypotheses to predict which patients 
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respond, including neoantigen prediction and in-
crease in mutational load. Also there are proposed 
response modifi ers to PD-1/PD-L1 inhibitors in uro-
thelial carcinoma including: Tumor-induced PD-L1 
or immunostimulatory neoantigen production, 
germline immune factors including immune micro-
environmental properties that can induce PD-1/PD-
L1 in monocytes, or increased activity in solid tu-
mors through new tumor antigens or tumor 
molecular subgroups that have signifi cantly in-
creased expression of immune genes. Exploring all 
these newly described potential mechanisms in blad-
der cancer clinical trials is a must. 
Many patients who demonstrate clinical benefi t 
with immunotherapy or targeted agents subsequent-
ly become resistant to therapy. Exploring the mech-
anisms of response and resistance to these agents is 
an important area of investigation with sequential 
biomarker studies. In urothelial cancer trials with 
targeted and immunotherapeutic agents, the contin-
ued interrogation of both tumor and tumor microen-
vironment, including the underlying germ line com-
ponents, will further accelerate the impact of the 
novel antitumor agents in bladder cancer patients.
BIOSPECIMEN ACQUISITION, QC AND 
LOGISTICS
Nilsa  Ramirez, M.D.
Overseeing the collection, processing, banking 
and distribution of biospecimens obtained from con-
sented patients enrolled in SWOG-sponsored clini-
cal trials is the responsibility of the SWOG Bio-
specimen Bank. This resource also assists 
investigators in numerous aspects of clinical trial 
development, including cost estimates for various 
projects (e.g., R01, pilot projects), histology ser-
vices (e.g., tissue microarray (TMA) creation, IHC 
stains), nucleic acid extractions, virtual microscopy, 
and informatics.
When an investigator (named as a co-investigator 
of a correlative science study integrated into the 
clinical trial design itself), requests biospecimens 
for a pre-approved study, the Bank works with the 
SWOG Statistical and Data Management Center so 
the selected biospecimens are distributed to the in-
vestigator following the instructions noted in the 
protocol. There is no fee for this specifi c Bank ser-
vice (covered by the SWOG U24 grant), unless 
highly specialized, expensive, or onerous biospeci-
men processing is required; in those cases, the work 
should be supported by the trial or correlative sci-
ence study budget, which is determined prior to the 
start of the study. In some cases, biospecimens that 
are remaining after the completion of trial-associat-
ed correlative science studies (legacy biospecimens) 
may be available for secondary use in other cor-
relative science studies. A scientifi c merit review 
process is required for research proposals before 
legacy biospecimen access is granted. Investigators 
within SWOG as well as external investigators are 
welcome to submit proposals for consideration. At 
this time the application process instructions are 
available at the SWOG website (http://www.swog.
org/Visitors/TranslationalMed.asp) under “Collab-
orative Use of Specimens for Translational Medi-
cine Research”. In this setting, a fee for service is 
required for biospecimen processing (including 
quality assurance) and distribution, as well as any 
additional testing (e.g., nucleic acid extractions, 
TMA creation). In the near future a new mechanism 
will be instituted in response to the NCTN Group 
reorganization and research community feedback. 
The new NCTN Core Correlative Science Commit-
tee, in conjunction with the NCTN Biospecimen 
‘Front Door Service’ and biospecimen Navigator 
tool, will improve the effi ciency and transparency 
of the biospecimen request process for the entire 
cancer research community. The NCTN Front Door 
staff will guide investigators through biospecimen 
query, application, and regulatory fi ling procedures. 
The web-based Navigator tool will allow investiga-
tors to independently query for Group Bank bio-
specimens that meet their criteria, and track their 
request through the review and approval process. 
Numerous other NCI supported bioresources are 
also available to assist investigators; for more infor-
mation, visit the NCI specimen resource locator 
(https://specimens.cancer.gov/tissue/default.htm).
HOW NCTN GROUPS WORK TOGETHER – 
DIFFERENT PARADIGM
Jeffrey Abrams, M.D., Bhupinder Mann, MBBS, 
 Abdul Tawab Amiri, Ph.D.
The NCI, for several decades, supported a system 
for conducting clinical trials in cancer through a 
number of national cooperative groups. The system 
served us well, and clinical trials led to advances in 
treatment of cancer. Nevertheless, improvements in 
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effi ciency were necessary as the resources were rap-
idly becoming limited, and with increasing use of 
molecular techniques, each disease was being rede-
fi ned as consisting of molecularly distinct subsets. 
Reorganization of the cooperative group system into 
the National Clinical Trials Network (NCTN) since 
2014 now offers the investigators several new plat-
forms for conducting clinical and correlative science 
research. One example of the reorganization is the 
increasingly central role of the Cancer Trials Sup-
port Unit (CTSU). CTSU worked with the network 
groups to implement Medidata Rave as a single data 
management tool, and all NCTN sites can now par-
ticipate in each other’s phase 3 and selected phase 
2 studies. In addition, the institutional review board 
procedures have been streamlined by increasing par-
ticipation in the NCI Central IRB (CIRB) for all 
NCTN phase 3 and selected phase 2 trials, and the 
time required for IRB approval has been dramati-
cally reduced by its use. Finally, the NCTN Bio-
specimen Navigator tool provides a comprehensive 
inventory of NCTN banked biospecimens and pro-
vides a single, unifi ed gateway for requests to use 
specimens collected on NCTN trials for correlative 
research. Navigator makes it possible to look across 
the NCTN to see what biospecimens and resources 
are available for innovative research projects.
Regarding the NCTN groups, the NCI has modi-
fi ed the incentives to stimulate more collaboration. 
Network groups are no longer required to lead a 
trial in each disease area in which they work [125]. 
Rather, they can succeed in peer review by leading 
some trials but also by participating actively in trials 
led by other network groups. Investigators are en-
couraged to collaborate across groups both via 
 accrual and by adding interesting correlative science 
objectives to individual trials, irrespective of the 
group leading the trial. In fact, if groups don’t col-
laborate well, they will be penalized at peer review. 
We expect that this boost in collaboration among 
the NCTN participants will allow the network to 
enroll faster to its trials, and fi nd answers faster for 
patients. The NCI Molecular Analysis for Therapy 
Choice (NCI-MATCH) clinical trial is a terrifi c ex-
ample of collaboration in the new system, with 15-
20 specifi c sub-protocols, each one having a Princi-
pal Investigator (PI) who is not necessarily a 
member of the lead group (ECOG-ACRIN Cancer 
Research Group) conducting the trial, but who can 
come from any of the network groups. Thus, we are 
already having much more integration of group in-
vestigators on this single protocol. 
With rapid developments in molecular biology, 
particularly in gene sequencing technology, ever 
increasing resources are becoming necessary, and 
this is occurring in an era of constrained budgets for 
NCI. Leveraging resources from non-governmental 
entities to help NCI conduct its clinical trials is be-
coming more critical. This was very clear in design-
ing Lung-MAP. We created a public-private partner-
ship to conduct this trial. The genomic sequencing 
for molecular alterations required for every patient 
entering this trial necessitated additional funds. So, 
we set up a collaboration that includes Friends of 
the Cancer Research (an advocacy organization), 
Foundation for the National Institutes of Health (the 
foundation used by the government to bring funds 
to NCI from outside organizations), and we had 
participation from the FDA in helping to design this 
trial. These partnerships are not without their own 
challenges as it does require that network groups 
adapt to these partnerships which require modifi ca-
tion of customary network group procedures. 
In closing, bladder cancer offers some similarities 
to squamous cell lung carcinoma as it may require 
screening of large numbers of tumors to fi nd those 
with a specifi c actionable gene alteration, given the 
relatively low (10–15%) frequency of these altera-
tions. Resources for screening large numbers of 
patients are necessary for successful conduct of such 
trials and need to be thought about at the early 
stages of developing the study. Hopefully, several 
new tools and platforms now operational in the 
NCTN will facilitate the conduct of these necessary 
yet complex trial designs. 
CONSENSUS DISCUSSION TO 
PRIORITIZE NCTN GROUP  T RIALS
MOLECULARLY TARGETED CLINICAL 
TRIAL IN PATIENTS  WITH NMIBC
Jonathan Rosenberg, M.D. and Eugene K. Cha, 
M.D.
The molecular target demonstrating the most 
promise for intervention at this time in NMIBC is 
the fi broblast growth factor receptor 3 (FGFR3). 
This gene is frequently mutated in this disease state, 
although the frequency of mutation declines with 
increasing grade and stage. FGFR3 activation ap-
pears to be an early event, and non-muscle-invasive 
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tumors are highly enriched for activating mutations 
and fusions. These FGFR3 alterations occur in 50-
70% of non-muscle-invasive bladder cancer 
(NMIBC), and are more prevalent in tumors of low 
grade and low stage [30–33, 36]. FGFR3 mutant 
tumors recur at the same frequency as FGFR3 wild-
type tumors, but have a lower rate of progression to 
muscle invasion, with one study demonstrating a 5 
year progression free survival of 91% in FGFR3 
mutant patients compared to 74% in FGFR3 wild-
type patients [36]. The FGFR3 mutation status in 
bladder tumor recurrences is often concordant with 
the primary tumor [37]. The high recurrence rate of 
NMIBC leads to signifi cant morbidity and health 
care spending due to the need for frequent cysto-
scopic monitoring and operative intervention. 
Therefore, an effective oral agent to reduce the re-
currence of NMIBC would be of high value.
Testing FGFR3 targeted agents in NMIBC re-
quires careful balancing of risks and benefi ts when 
considering trial designs. These agents are currently 
being investigated as systemic agents, and do not 
currently have intravesical formulations. Therefore, 
the potential toxicity of the treatment must be bal-
anced with the risk of the disease under treatment. 
In addition, systemic toxicity is observed with these 
drugs (e.g. hyperphosphatemia, keratopathy, fa-
tigue), although they are readily reversible upon 
cessation of the study drug. Studies to demonstrate 
anti-tumor activity are required to determine wheth-
er systemic administration of FGFR3 inhibitors can 
lead to anticancer effects on tumors in the lining of 
the bladder. These pilot studies would provide the 
rationale for larger “adjuvant” or post-TUR studies 
which are time-to-event driven studies. 
One study design using a “marker lesion” was 
heavily discussed at the meeting. This design re-
quires that a small (≤1cm) non-invasive appearing 
tumor is left in place while systemic therapy is ad-
ministered. The use of a marker lesion within the 
bladder has precedent in multiple phase II studies 
of NMIBC [6, 44–49]. These studies used the mark-
er lesion to determine the ablative effect of therapy. 
These pilot studies can demonstrate preliminary 
evidence of anti-cancer activity that would justify 
larger trials. However, these studies have some ad-
ditional, albeit low, risk to patients in that a small 
tumor is left in place for a period of time. To mini-
mize this risk, any remaining tumor is removed af-
ter 2-3 months of treatment. This time period has 
been demonstrated to be safe, though very rare in-
cidences of progression have been reported.
An alternative approach is the “window of op-
portunity” trial, which takes advantage of the inter-
val between identifi cation of recurrent tumor on 
offi ce cystoscopy, and the operative TUR, usually 
performed several weeks later. The investigational 
agent is given for a defi ned, relatively short, period 
of time, and the anti-tumor activity is evaluated at 
transurethral resection. This approach requires map-
ping of the tumors present prior to initiation of 
therapy, and then re-evaluation at TUR after a de-
fi ned period of time. This approach also allows as-
sessment of anti-tumor ablative activity of an ex-
perimental agent. To be safe, this approach requires 
that only a limited therapeutic course is adminis-
tered, as the entire tumor(s) is left in place. Defi ning 
success short of complete response is controversial, 
as measurement of tumor in situ in the bladder is 
quite diffi cult, and so shrinkage but not disappear-
ance would be diffi cult to accurately quantify.
Discussion focused on the acceptability of the 
marker lesion concept to patients and physicians. 
While the marker lesion design as been shown to 
be safe, there is a theoretical risk of progression 
during the interval of treatment (shown to be <1%). 
Therefore, a majority of the participants felt that a 
window-of-opportunity study would be a more ac-
ceptable approach. Concepts are under development 
to test FGFR3 inhibitors using this study design.
IMMUNOLOGY-BASED CLINICAL TRIAL 
IN PATIENTS WITH  NMIBC
Noah M. Hahn, M.D.
Given the wide array of immune checkpoint in-
hibitor and agonist therapies currently being tested 
for safety and initial effi cacy in multiple ongoing 
clinical trials, a broad multi-arm phase Ib trial de-
sign to be led by ECOG-ACRIN was proposed in 
patients with NMIBC who have recurred after in-
duction BCG (BCG failure) patients to test the 
safety of modern immune therapies as monothera-
py, in combination with intravesical BCG, and in 
combination with external beam radiation therapy 
as depicted in the schema in Fig. 8. The study 
schema shown is meant to represent all rational 
immune therapy targets suitable for combination 
with BCG for which phase I clinical trial safety 
data exists or is expected in the next 6-12 months. 
It is anticipated that the eventual number of trial 
arms will be less than is shown in the schema. The 
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exact number of arms will be dictated by sponsor 
interest and safety data as it emerges. A short phase 
I lead-in design is anticipated in each arm. The 
immunotherapy agent of interest will not be dose 
reduced. If dose limiting toxicity is encountered 
amongst the fi rst 6 patients in a study arm, an ad-
ditional 6 patients may be enrolled at one-third 
dose BCG. It is anticipated that a cap will be placed 
on the number of Ta/T1 patients within each arm 
to ensure an adequate number of CIS-only patients 
in each arm such that confi dence interval estimates 
of the 6-month relapse free survival rate within 
NMIBC patient subsets will be of value in making 
decisions about subsequent phase II/III registration 
trial designs (i.e. Ta/T1 compared to CIS-only). 
Lastly, the study is envisioned as utilizing a fl ex-
ible randomization strategy similar to the recently 
reported STAMPEDE prostate cancer trial (https://
clinicaltrials.gov/show/NCT00268476) in which 
patients will be randomized between arms open to 
accrual [126]. In such a design, arms can be added 
in or taken out throughout the life cycle of the 
trial based on emerging safety data or new target 
identifi cation. 
After a summary of the day 1 immuno-oncology 
discussion points and a thorough deliberation of the 
proposed clinical trial concepts from day 1, a con-
sensus was reached on the following three themes:
1.  While there are expected to be several single-arm 
industry-sponsored trials in the BCG-unrespon-
sive NMIBC population making competition for 
patient accrual fi erce, the collective ability of 
intergroup investigators to make major transla-
tional contributions to the fi eld in this population 
is immense. Therefore, a trial design in BCG-
unresponsive patients with a PD-1 or PD-L1 
checkpoint inhibitor should be pursued and sup-
ported by intergroup investigators.
2.  A trial design of combined immune checkpoint 
blockade (i.e. anti-CTLA-4 therapy plus anti-
PD-1 or anti-PD-L1 therapy) in combination with 
intravesical BCG posed too high of a risk for 
serious adverse events in a BCG-relapsing 
NMIBC population and should not be pursued at 
this time.
3.  An early phase trial design incorporating modern 
immunotherapy agents as monotherapy, in singu-
Fig. 8. Preliminary schema proposed for a broad multi-arm phase Ib trial in NMIBC patients who 
have recurred after induction BCG to test immune therapies in combination with intravesical BCG 
and with external beam radiation therapy.
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lar combinations with intravesical BCG, and in 
combination with external beam radiation thera-
py received widespread support and should be 
pursue d. 
As a result of the session 2 discussions, both a 
concept by led by SWOG of anti-PD-L1 therapy in 
BCG-unresponsive and a multi-arm concept of mod-
ern immunotherapy agents as monotherapy, in com-
bination with BCG, or in combination with external 
beam radiation therapy (EBRT) led by ECOG-
ACRIN in BCG-relapsing patients were endorsed 
by the group to proceed forward for development as 
intergroup clinical trials.
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